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A B S T R A C T
Background
Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in
order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antineoplastic
therapy.
Objectives
To evaluate the effectiveness of pTE and sTP for the management of cancer.
Search strategy
We searched CENTRAL (The Cochrane Library 2010, Issue 3), MEDLINE, EMBASE, AMED, BIOETHICSLINE, BIOSIS, CAT-
LINE, CISCOM, HEALTHSTAR, HTA, SOMED and LILACS (to February 2010).
Selection criteria
Randomised trials of pTE or sTP in addition to chemotherapy or radiotherapy, or both, compared to the same regimen with placebo
or no additional treatment in adult cancer patients.
Data collection and analysis
Two authors independently extracted data from published trials. We derived odds ratios (OR) from overall survival (OS) and disease-
free survival (DFS) rates, tumour response (TR) rates, and rates of adverse effects (AE) related to antineoplastic treatments. We used a
random-effects model for meta-analysis.
Main results
We identified 26 trials (2736 patients). Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated
sTP (thymopentin or thymosin α1). Twenty-one trials reported results for OS, six for DFS, 14 for TR, nine for AE and 10 for safety
of pTE and sTP. Addition of pTE conferred no benefit on OS (RR 1.00, 95% CI 0.79 to 1.25); DFS (RR 0.97, 95% CI 0.82 to 1.16);
or TR (RR 1.07, 95% CI 0.92 to 1.25). Heterogeneity was moderate to high for all these outcomes. For thymosin α1 the pooled RR
for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14), with low heterogeneity; and 3.37 (95% CI 0.66 to 17.30, P = 0.15) for DFS, with
moderate heterogeneity. The pTE reduced the risk of severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008; I²
= 0%). The RR for severe neutropenia in patients treated with thymostimulin was 0.55 (95% CI 0.25 to 1.23, P = 0.15). Tolerability
of pTE and sTP was good. Most of the trials had at least a moderate risk of bias.
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Authors’ conclusions
Overall, we found neither evidence that the addition of pTE to antineoplastic treatment reduced the risk of death or disease progression
nor that it improved the rate of tumour responses to antineoplastic treatment. For thymosin α1, there was a trend for a reduced risk of
dying and of improved DFS. There was preliminary evidence that pTE lowered the risk of severe infectious complications in patients
undergoing chemotherapy or radiotherapy.
P L A I N L A N G U A G E S U M M A R Y
Thymic peptides for treatment of cancer patients in addition to chemotherapy or radiotherapy, or both
The immune system plays a key role in the body’s own defences against cancer cells. The thymus gland plays a central part in this
and modifies T-cells, a subset of lymphocytes. Studies with thymic peptides have shown a variety of effects on the immune system.
There are two groups of thymic peptides available for use in treatment: purified extracts from animal (mostly calf ) thymus glands and
synthetically produced thymus gland peptides.
This review aims to answer the question whether having thymic peptides can improve the response to and tolerability of standard
chemotherapy or radiotherapy, or combined treatment. Further questions are whether the peptides inhibit or reduce the progression
and recurrence of disease, whether they prolong the life of cancer patients and whether quality of life is improved.
This review looked at the evidence from 26 clinical trials with a total of 2736 adult cancer patients. Many of the trials were small
and of moderate quality. Only three studies were less than 10 years old. Thymosin α1 is a synthetic peptide that shows some promise
as a treatment option for patients with metastatic melanoma when used in addition to chemotherapy. Severe problems occur during
chemotherapy and radiotherapy due to low white blood cell counts and infections. These were reduced by using purified thymus
extracts. However, the use of purified thymus extracts should be investigated more thoroughly before the extracts are used routinely in
patients. The findings were not conclusive and caution is advised. Overall, thymic peptides seem to be well tolerated.
B A C K G R O U N D
By the late 1950s and early 1960s the role of the thymus as a lym-
phoid organ became clearer based on observations of a decreased
immune response and consequent lowered resistance to infectious
disease that resulted from damage to or experimental removal of
the gland (Seybold 1950). It is now well established that the thy-
mus gland is a central lymphoid organ in which bone marrow-
derived T-cell precursors undergo differentiation within the con-
text of a specific cellular and extracellular microenvironment. The
thymus gland is also responsible for the production of various pep-
tides with hormone-like activity and purified extracts from animal
thymus glands have been used to treat primary immunodeficient
states (Goldstein 2009).
The role of the immune system to recognize and destroy tumour
cells has been hypothesized since the early 1950s and is now gen-
erally accepted (Dunn 2002). One of the approaches to treat can-
cer is via stimulation or modulation of the immune system with
extracts and peptides from the thymus gland, which was first in-
troduced in the 1970s (Costanzi 1977).
Thymus derived pharmaceuticals can be divided into two groups:
1. purified extracts from animal thymus glands containing
peptide mixtures; and
2. synthetically produced single thymic peptides.
Historically these two groups represent two steps in the investiga-
tion of thymic peptides involved in T-cell maturation and activa-
tion. The first step is to produce cell-free extracts, the second is to
characterize and analyse single components of these extracts.
Purified thymus extracts
Extracts from calf thymus glands were further processed in dif-
ferent steps of purification, fractionation and filtration to result
in peptide mixtures. The exact composition and character of the
peptides are not completely known and are subject to biological
variation. Different preparations are not defined by their compo-
nents but by the respective standardization of the extraction pro-
cedure. Two purified thymus extracts (pTE) were investigated in
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clinical trials and are included in this review, thymosin fraction 5
and thymostimulin (Table 1).
Table 1. Type of interventional treatment
Type Name Ingredients Provider Applied in study
Purified thymus extracts Thymosin fraction 5 Peptide mixture, range 1-
15 kDa
Hoffmann-La Roche Bedikian 1984; Cohen
1979; Scher 1988; Wara
1981
Thymostimulin Peptide mixture, range 1-
12 kDa
Serono S.A. Airoldi 1987; Canovas
1988; Canovas 1991; De
Serdio 1997; Del Giacco
1988; Federico 1995;
Gonnelli 1995; Guzman
1988; Iaffaioli 1994;
Luzi 1984; Macchiarini
1989; Mantovani 1988;
Mustacchi 1994; Pavesi
1993; Salvati 1984;
Sanchiz 1996
Synthetic thymic pep-
tides
Thymosin α1 Polypeptide (28 amino
acids)
SciClone
Pharmaceuticals
Cheng 2004; Gish 2009;
Maio 2010; Schulof 1985
Thymopentin Oligopeptide (5 amino
acids)
Italfarmaco Gebbia 1994; GISOT
1987
Thymosin fraction 5
Thymosin fraction 5 was produced by US investigators in 1966.
Goldstein et al extracted a so called ’lymphocytopoietic factor’
from calf thymus, referring to its capacity to stimulate proliferation
of lymphocytes both in vitro and in animal models, and termed it
thymosin, which was initially thought to be a single polypeptide
(Goldstein 1966). A further 5-step purification led to ’thymosin
fraction 5’, then identified as a mixture of 30 to 40 small polypep-
tide components with a molecular weight ranging from 1 to 15
kilodalton (Goldstein 1977).
Thymostimulin
Thymostimulin, also extracted from calf thymus, was first pro-
duced by Italian investigators in 1976. It consists of a group of
peptides with molecular weights ranging from 1 to 12 kilodalton
(Falchetti 1977). The way of processing differs from that of thy-
mosin fraction 5 in several steps, which presumably results in a
different composition of peptides (reviewed in Schulof 1985a).
Synthetic thymic peptides
Synthetically produced thymic peptides (sTP) are derivatives of
peptides that have been isolated from thymus extracts and se-
quenced. Two synthetically produced thymic peptides were used
in clinical trials included in this review, thymosin α1 and thy-
mopentin (Table 1).
Thymosin α1
Thymosin α1 is a peptide of 28 amino acids that was first isolated
from thymosin fraction 5 in 1977 (Goldstein 1977). It is highly
conserved among species and the amino acid sequence of human
and bovine thymosin α1 are identical (reviewed in Hannappel
2003). Thymosin α1 has been sequenced and produced synthet-
ically. Nowadays it is approved, mainly in countries of Asia and
South America, for the treatment of chronic hepatitis B and C
as a vaccine enhancer and in few countries of Southeast Asia for
the treatment of cancer (Billich 2002). Pharmacokinetic studies
in healthy volunteers showed good absorption after subcutaneous
injection with a peak serum level at between one and two hours
3Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and a half live of less than three hours (Rost 1999).
Thymopentin
Thymopentin is a fragment of a larger peptide called thymopoi-
etin. Thymopoietin was initially isolated from calf thymus and
consists of 49 amino acids. It had been shown to induce differen-
tiation of T-cell precursors both in vitro and in vivo (Schlesinger
1975). In the search for a smaller peptide with the same immuno-
logic properties that was suitable for large-scale synthesis, the five
amino-acid peptide thymopentinwas identified (Goldstein 1979).
Pharmacokinetic studies in humans showed a short half live of 30
seconds (reviewed in Singh 1998).
Preclinical and clinical studies with pTE and sTP
Preclinical studies with pTE and sTP showed a variety of modula-
tory effects on the immune system (Bodey 2000; Chretien 1978;
Goldstein 2009; Schulof 1985a). They were tested with other sub-
stances in the Biological Response Modifiers Program of the Na-
tional Cancer Institute for their efficacy in the treatment of human
cancers in the 1980s (Schulof 1985a). Surveys from the late 1990s
showed ample dissemination of information on the treatment of
cancer with purified thymus extracts as part of a ’complementary
and alternative treatment’ of cancer (Grothey 1998;Hardell 1998;
Kullmer 1999; Moschen 2001; Sehouli 2000; Soellner 1997).
Clinical studies investigated the effects on various clinical end-
points as well as immunological effects in a broad range of malig-
nant diseases. The findings of controlled trials of pTE and sTP in
cancer have not been conclusive. The height of research activity
was in the 1980s and early 1990s and then seemed to wane but
very recently published studies with thymosin α1 indicate that it
is still topical (Maio 2010).
The purpose of this reviewwas to summarize the available evidence
from clinical trials which investigated pTE and sTP in combina-
tion with chemotherapy or radiotherapy, or both, in order to de-
termine whether the addition of thymic peptides had a beneficial
effect on survival outcomes and quality of life in cancer patients
as well as whether it improved the response to and tolerability of
conventional cancer therapies. Given the diversity of pTE and sTP
we also intended to elucidate their probable differential effects.
O B J E C T I V E S
To determine the effectiveness and tolerability of purified thymus
extracts (pTE) and synthetically produced thymic peptides (sTP)
for the treatment of cancer patients during chemotherapy or ra-
diotherapy. The objectives of the review were to assess the follow-
ing.
• The effects of thymic peptides on:
◦ overall survival (OS) and disease-free survival (DFS) or
progression-free survival (PFS),
◦ tumour response,
◦ adverse effects of chemotherapy and radiotherapy,
◦ patient-reported quality of life.
• Adverse effects of pTE and sTP;
and to make recommendations for future research.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or quasi-RCTs (for example
trials which used alternation, allocation by date of birth, etc.).
Types of participants
Adult patients with histologically proven malignant diseases of
all stages who were submitted to treatment with chemotherapy,
chemo-immunotherapy or radiotherapy (that is standard care).
Types of interventions
Intervention group
Standard care plus treatment with any kind of parenterally applied
pTE or sTP.
Control group
Standard care plus placebo treatment or no additional treatment.
Standard care was required to be similar between groups.
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Types of outcome measures
The outcomes of interest were:
• OS;
• DFS and PFS;
• tumour response (parameters for response had to be defined
or follow standard criteria (WHO (Miller 1981), RECIST
(Therasse 2000));
• hematologic toxicities or infectious complications related to
antineoplastic treatment (chemotherapy, radiotherapy) of at least
grade 3, scored using standardized criteria (CTC version 2 or
later) (CTC 2009);
• adverse events related to pTE and sTP.
Quality of life (QoL),measuredwith validated instruments, was an
outcome for which data were sought but no data for this outcome
were found in any of the includedRCTs.Trialswhich only reported
physiologicalmeasures (for example immune parameters etc.) were
excluded.
For a glossary of terms please see Appendix 1.
Search methods for identification of studies
The last systematic search was performed in February 2010.
Electronic searches
We searched the following databases without language restrictions:
CochraneComplementaryMedicine FieldRegistry of randomised
clinical trials and controlled clinical trials, CochraneCentral Regis-
ter of Controlled Trials (CENTRAL) (TheCochrane Library 2010,
Issue 3), MEDLINE, EMBASE, PubMed, AMED, BIOETHIC-
SLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, IN-
TERNATIONAL HEALTH TECHNOLOGY ASSESSMENT,
SOMED, LILACS. Synonyms of the specific termswere identified
by looking up the thesaurus of each database, if available. Search
strategies and terms are listed in Appendix 2. All databases were
searched from inception to February 2010.
Duplicates were removed from the search results and bibliogra-
phies from retrieved articles were searched for additional studies.
The search strategies used were developed and executed by the
author team.
Searching other resources
To minimize the impact of publication bias, we searched confer-
ence abstracts and unpublished material. Inquiries were sent to
the investigators or institutions of included studies and respective
manufacturers of pTE and sTP requesting information on addi-
tional trials. Our own files were searched for further studies.
Data collection and analysis
All discrepancies between two authors in the process of data col-
lection and analysis were discussed and, if not agreed upon, the
opinion of a third review author was sought.
Selection of studies
All publications identified by the search were screened by one re-
view author (SM), who excluded those that were clearly irrelevant
(for example diseases other than cancer, reviews, etc.). The titles
and abstracts of the remaining articles were independently checked
by two review authors (KB, MH, SM, EW). When articles could
not be excluded with certainty, full text material was obtained. At
least two review authors (KB,MH, SM, EW) of the team indepen-
dently assessed full text material by means of a standard eligibility
form that applied the inclusion and exclusion criteria. All results
of the selection process were documented and disagreements re-
solved by discussion with a third review author (MH, EW).
Data extraction and management
Data extraction was performed non-blinded to the study authors
and independently by at least two review authors using a pretested
extraction form. For included studies, data were extracted as rec-
ommended inHiggins 2009. This included data on the following.
• Author, year of publication (if published), journal citation
and language.
• Country.
• Setting.
• Study design, methodology.
• Study population: total number enrolled, patient
characteristics (inclusion and exclusion criteria, age, stage,
histological cell type, co-morbidity, previous treatment), number
enrolled in each arm.
• Intervention and control details: no treatment, composition
of placebo.
• Standard care: type of chemotherapy, number of cycles and
dose; timing and dose of radiotherapy.
• Risk of bias in study: see below.
• Duration of follow up.
• Deviations from protocol.
• Outcomes, where data on all outcomes were extracted for:
◦ time to event data, we extracted the median or mean
survival times and their spread or confidence interval;
◦ dichotomous outcomes (e.g. adverse events, deaths,
disease recurrence, disease progression, tumour response), we
extracted the number of patients in each treatment arm who
experienced the outcome of interest and the number of patients
assessed at the endpoint in order to estimate a risk ratio (RR). If
necessary, data were extracted from Kaplan-Meier curves;
◦ adverse events, type of event and grade of toxicity.
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The time points at which outcomes were collected and reported
were noted. Data were entered from the forms into a Microsoft
Access database and double-checked using descriptive database
methods andplausibility checks by two review authors (MH,EW).
If more than one report from a study was available, themost recent
was considered as the primary publication and was used primarily
for data extraction; information from other reports were extracted
if not reported in the primary reference. Data from non-english
articles were extracted with the help of a native speaker.
Assessment of risk of bias in included studies
The assessment of risk of bias was carried out according to the
approach of The Cochrane Collaboration (Higgins 2009). In a
first step, information relating to study quality that was essential
for the judgment of risk of bias was extracted onto a prespecified
form. Two review authors (MH, EW) then independently judged
the risk of bias for each criterion as being low, high or unclear.
Disagreements were resolved by discussion. The ’blinding’ item
was split up in order to allow for differential assessment of the
outcomes dependent or independent of outcome assessors. The
risk of bias was scored ’low’ to ’high’ with three intermediates
(’low tomoderate’, ’moderate’, and ’moderate to high’), with ’high’
indicating the highest risk of bias.
Dealing with missing data
Where information was missing in the study reports, lacked de-
tail or there was a discrepancy between different reports, we tried
to obtain the required information from the study authors. Con-
tacting study authors helped to clarify our questions for only one
publication (Maio 2010).
Assessment of heterogeneity
Heterogeneity was assessed according to the standard method us-
ing the I2 statistic, calculated for each comparison on each out-
come. I2 values above 50% indicated high heterogeneity, between
25% and 50% moderate heterogeneity, and below 25% low het-
erogeneity.
Data synthesis
For both survival outcomes,OS andDFS, we analysed the number
of patients in each treatment arm who experienced deaths from all
causes or relapse or progression of their cancer disease at one year
± four months. Tumour response was analysed if studies reported
events of complete or partial, or both, responses. Pooled random-
effects model estimates and their 95% confidence intervals (CI)
were calculated. Analyses were run separately for pTE and sTP
trials.
A decision regarding whether to combine treatment-related symp-
toms was made depending on how this information was collected
in each trial. Results were expressed as relative risks or risk ratios
(RR) with 95% CIs. In survival and tumour response analyses
a RR higher than 1.0 favoured the intervention group, indicat-
ing that patients in the intervention group (pTE or sTP) had a
greater chance of survival or for having a response to treatment.
In the analysis of adverse effects of chemotherapy and radiother-
apy, RR less than 1.0 favoured the intervention group, indicating
that fewer patients experienced adverse events in the intervention
groups than in the control group.
In studies reporting the median survival time, we recalculated the
number of events up to median survival time in the intervention
group for both the intervention and the control group assum-
ing one-parametric exponential survival time. This assumption is
equivalent to assuming a constant event hazard Ê. Therefore, the
formulae developed by Kirkwood 2003 were used (Appendix 3).
Due to the variable study methods, all meta-analyses were consid-
ered as being explorative and pooled effects sizes have to be inter-
preted with great caution.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were performed according to type of pTE or
sTP if at least three studies reported data on the respective outcome
and carried out sensitivity analyses as described below.
Sensitivity analysis
We performed sensitivity analyses taking account of different in-
tervention treatments within one study (that is low dose or high
dose of thymic peptides).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
See: Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
From electronic searches and handsearches we retrieved 326 rele-
vant publications. Out of 326 publications, 23 publications were
unclear or the abstracts were not retrievable and 251 publications
were ineligible for this systematic review. Reasons for ineligibility
were: trial design other than RCT (for example historical control
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group); participants other than adult cancer patients (for example
children, other disease conditions); no thymic peptides; applica-
tion mode other than subcutaneous or intramuscular (for example
oral or topical) or combination with other substances; no control
for thymic peptides; and no chemotherapy or radiotherapy or dif-
ferent regimes in the control and intervention groups.
Included studies
Twenty-six randomised controlled trials were included in this re-
view. Thirteen were conducted in Italy (Airoldi 1987; Del Giacco
1988; Federico 1995;Gebbia 1994;GISOT1987;Gonnelli 1995;
Iaffaioli 1994; Luzi 1984; Macchiarini 1989; Mantovani 1988;
Mustacchi 1994; Pavesi 1993; Salvati 1984), six in the USA
(Bedikian 1984; Cohen 1979; Gish 2009; Scher 1988; Schulof
1985; Wara 1981), four in Spain (Canovas 1988; Canovas 1991;
De Serdio 1997; Sanchiz 1996), one inArgentina (Guzman 1988),
one inChina (Cheng 2004), and one study recruited patients from
several countries (Maio 2010). Studies with thymosin fraction 5
were published between 1979 and 1988, with thymostimulin be-
tween 1984 and 1997, with thymopentin between 1987 and 1994,
and with thymosin α1 between 1985 and 2010.
Participants
A total of 2931 adult patients were randomised (and 2744 eval-
uated) in the studies (median 49, range 28 to 650). The stud-
ies included the following number of randomised (and evaluated)
cancer patients:
• four studies with 427 (372 evaluated) breast cancer patients
(Gonnelli 1995; Mantovani 1988; Pavesi 1993; Sanchiz 1996),
• five with 314 (304) non-small cell lung cancer patients
(Bedikian 1984; Del Giacco 1988;Iaffaioli 1994; Luzi 1984;
Schulof 1985),
• four with 220 (192) small cell lung cancer patients (Cohen
1979; Macchiarini 1989; Salvati 1984; Scher 1988),
• three with 236 (207) lymphoma patients (Canovas 1988;
Canovas 1991; Federico 1995),
• three with 160 (159) head and neck cancer patients (Airoldi
1987; De Serdio 1997; Wara 1981),
• two with 267 (243) colorectal cancer (Guzman 1988;
Mustacchi 1994),
• two with 69 (66) hepatocellular carcinoma patients (Cheng
2004; Gish 2009),
• two with 750 (705) patients with various types of cancer
(Gebbia 1994; GISOT 1987), and
• one with 488 (488) melanoma patients (Maio 2010).
Treatments
Intervention
In 20 studies pTE was used as interventional treatment: 16 used
thymostimulin and four used thymosin fraction 5. Thymostim-
ulin was applied intramuscularly and single doses ranged from 25
mg to 150 mg. Most study authors (n = 9) used a dose of 1 mg/
kg body weight. Thymosin fraction 5 was applied subcutaneously
with single doses of 60 mg in all trials. However, treatment sched-
ules varied considerably among trials. Cohen 1979 had two inter-
ventional arms with different doses of thymosin fraction 5 (20 mg
and 60 mg).
Six study authors used sTP as the interventional treatment: four
used thymosin α1 and two used thymopentin. Thymosin α1 was
applied subcutaneously with single doses of 1.6 mg in three trials
and 0.9 mg/m² in one trial. Treatment schedules varied among
these trials. Maio 2010 compared different doses of thymosin α1
(1.6, 3.2 and 6.4 mg); Schulof 1985 compared a 14-day ’loading’
dose of thymosin α1 with a maintenance therapy for up to one
year; thymopentin was given intramuscularly in Gebbia 1994 and
subcutaneously in GISOT 1987, both studies using single doses
of 50 mg.
Control
Twenty studies had two arms and two of these studies used a
placebo control (Iaffaioli 1994; Schulof 1985). Three studies had
three arms (Cheng 2004; Cohen 1979; Schulof 1985). Cohen
1979 compared two different thymosin fraction 5 doses with
no treatment; Cheng 2004 compared intrahepatic chemotherapy,
with or without thymosin α1, with no intrahepatic chemotherapy;
and Schulof 1985 compared two different regimen of thymosin
α1 with placebo. Gebbia 1994 had four arms and compared thy-
mopentin with or without granulocyte colony-stimulating factor
(G-CSF) versus placebo and G-CSF. Maio 2010 had five arms:
three compared different doses of thymosin α1 in addition to che-
motherapy plus interferon α, one arm had 3.2 mg thymosin α1
in addition to chemotherapy alone and the fifth arm had only
chemotherapy plus interferon α. The comparison between 3.2mg
thymosin α1 and interferon α was not included in the analysis as
interferon α was not a control treatment in accordance with our
protocol.
Basic treatment
The chemotherapy or radiotherapy regimen was described in all
but one of the studies (GISOT 1987). In 23 studies patients re-
ceived chemotherapy alone, in combination with radiotherapy or
immunotherapy, or applied as transcatheter arterial embolization.
In two studies patients received radiotherapy alone (Schulof 1985;
Wara 1981).
Outcomes
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Survival
Twenty-one studies reported OS. One author did not present es-
timates but described the results narratively (Iaffaioli 1994). Six
studies reported DFS (Cohen 1979; De Serdio 1997; Federico
1995; Guzman 1988; Mantovani 1988; Scher 1988), although
none gave a definition of how this was measured. Nine studies
reported on PFS (Airoldi 1987; Cheng 2004; Macchiarini 1989;
Maio 2010; Mustacchi 1994; Pavesi 1993; Salvati 1984; Schulof
1985;Wara 1981) although none gave a definition of how this was
measured. Terminology of the measures of relapse and recurrence
differed considerably between trials (Table 2, Table 3).
Table 2. Purified thymus extracts: survival, response, toxicity
Study Survival rates Tumour response Toxicity (no. of patients)
Overall survival
(OS)
Disease-/pro-
gression-free
survival (DFS/
PFS)
Complete
remission
Partial
remission
Grade 3/4 neu-
tropenia
Grade 3/4 infec-
tion
Airoldi 1987 After a median
time of survival
in IG of 7.9
months§:
IG: 12/24
(50%)
CG: 10/24
(42%)
After a median
time ofDFS in IG
of 3.8 months§:
IG: 7/14 (50%)
CG: 2/6 (33%)
After 8 cycles of
chemotherapy:
IG: 3/24
(12.5%)
CG: 1/24 (4%)
IG: 11/24
(46%)
CG: 5/24 (21%)
(p< 0.05 chi²
test)
n.r.
Bedikian 1984 After 1 year#:
IG: 8/46 (17%)
CG: 16/53
(30%)
(P = 0.14)
n.r. IG: 0/46
CG: 2/53 (4%)
IG: 10/46
(22%)
CG: 22/53
(42%)
n.r.
Canovas 1988 After 4 cycles of
chemotherapy
(approximately 3
to 4 months):
IG: 23/23
CG: 20/23
(87%)
n.r. n.r. n.r.
Canovas 1991 After 6 cycles of
chemotherapy
(approximately 4
to 6 months):
IG: 19/20
(95%)
CG:17/20
(85%)
n.r. n.r. n.r. (“life threatening
infections”)
IG: 2/20 (10%)
CG: 4/20 (5%)
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Table 2. Purified thymus extracts: survival, response, toxicity (Continued)
Cohen 1979 After 1 year#:
IG1 (60 mg/m²)
: 10/18 (56%)
IG2 (20 mg/m²)
: 2/12 (17%)
CG: 3/16 (19%)
After 1 year (com-
plete responders):
IG1: 6/9 (67%)
IG2: 1/2 (50%)
CG: 2/8 (25%)
After 3 months of
chemotherapy:
IG1: 9/18
(50%)
IG2: 2/12
(17%)
CG: 8/16 (50%)
n.r. n.r.
De Serdio 1997 n.r. After a mean time
of observation of
18 months:
IG: 15/18
(83%)
CG: 14/18
(78%)
Af-
ter approximately
2 months of ra-
diochemother-
apy:
IG: 17/18
(94%)
CG: 17/18
(94%)
n.r. n.r.
Del Giacco 1988 After 12 to 33
months observa-
tion time:
IG: 8/25 (32%)
CG: 8/23 (35%)
n.r. After
induction chemo-
therapy (only re-
ported in prelimi-
nary publication)
:
IG: 0/10
CG: 0/12
IG: 0/10
CG: 0/12
n.r. (lethal
infections)
IG: 0/25
CG: 2/23 (9%)
Federico 1995 After 1 year#:
IG: 51/66
(72%)
CG: 48/68
(71%)
(P = 0.62)
Pats. with CR
IG: 35/39
(90%)
CG: 24/29
(83%)
After completion
of chemotherapy
(approximately 3
to 6 months):
IG: 39/66
(59%)
CG: 29/68
(43%) (P = 0.05
log-rank)
IG: 14/66
(21%)
CG: 22/68
(32%)
n.r.
Gonnelli 1995 n.r. At 3 months of
chemotherapy (40
patients
evaluated):
IG: 0/20
CG: 0/20
IG: 1/20 (5%)
CG: 0/20
n.r.
At 6 months of
chemotherapy (36
patients
evaluated):
IG: 6/19 (32%)
CG: 4/17 (24%)
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Table 2. Purified thymus extracts: survival, response, toxicity (Continued)
IG: 0/19
CG: 0/17
Guzman 1988 After 18 to 42
months observa-
tion time:
IG: 14/16
(87.5%)
CG: 11/16
(69%)
IG: 11/16
(69%)
CG: 10/16
(62.5%)
n.r. n.r.
Iaffaioli 1994 n.r. n.r. (grade 3/4)
IG: 7/37 (19%)
CG: 12/32
(37.5%)
(P = 0.074)
n.r.
Luzi 1984 After 1 year#:
IG: 8/25 (32%)
CG: 6/25 (24%)
n.r. At 40 days (response was defined as
CR, PR or radiologic improvement of
atelectasis):
IG: 13/23 (57%)
CG: 21/24 (88%)
n.r.
Macchiarini
1989
After 1 year#:
IG: 10/15
(67%)
CG: 2/11 (18%)
(log rank
p<0,0032)
After
a median time of
DFS/PFS in IG of
6 months§:
IG: 7/15 (47%)
CG: 3/11 (27%)
After approx-
imately 6 months
of chemotherapy:
IG: 7/15 (47%)
CG: 1/11 (9%)
(P = 0.45, Fisher
exact)
IG: 4/15 (27%)
CG: 3/11 (27%)
(n.s.)
(grade 3)
IG: 0/15
CG: 3/11 (27%)
(grade 4)
IG: 0/15
CG: 1/11 (9%)
n.r.
Mantovani 1988 After 1 or 2 years:
IG: 18/20
(90%)
CG: 16/17
(94%)
(n.s.)
After 1 year:
IG: 6/11 (55%)
CG: 3/10 (30%)
After 2 years:
IG: 2/9 (22%)
CG: 4/7 (57%)
n.r. n.r.
Mustacchi 1994 After
a median time of
survival in IG of
10 months§:
IG: 53/106
(50%)
CG: 60/105
(57%)
After a median
time of DFS/PFS
in IG of 6.5
months§:
IG: 62/106
(58%)
CG: 62/105
(59%)
IG: 6/106 (6%)
CG: 3/105 (3%)
IG: 26/106
(25%)
CG:16/105
(15%) (P = 0.02,
chi²)
n.r.
Pavesi 1993 After a median
time of survival
After
a median time of
“Overall response” (not further de-
scribed):
n.r.
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Table 2. Purified thymus extracts: survival, response, toxicity (Continued)
in IG of ap-
proximately 16 to
17months§:
IG: 74/148
CG: 85/148
survival in IG of
15 months§:
IG: 74/148
CG: 86/148
IG: 77/148 (52%)
CG: 88/148 (60%)
Salvati 1984 After a median
time of survival
in IG of 6 for
extensive and 18
months for lim-
ited disease§:
IG: 12/23
(52%)
CG: 7/23 (30%)
After a median
time of survival
in IG of 2.1 for
extensive and 2.8
months for lim-
ited disease§:
IG: 11/23
(48%)
CG: 3/23 (13%)
IG: 6/20 (32%)
CG: 3/20 (16%)
IG: 6/20 (30%)
CG: 9/20 (45%)
n.r.
Sanchiz 1996 n.r. After 1 cycle of
chemotherapy:
IG: 0/27
CG: 0/27
IG: 1/27 (3%)
CG: 0/27
(grade 4)
IG: 20/27
(74%)
CG: 27/27
(p<0.01)
(ANC <500/
mm² and fever >
38°C)
IG: 6/27 (22%)
CG:
16/27 (59%) (P
= 0.0119)
Scher 1988 After 1 year#:
Limited disease:
IG: 11/17
(65%)
CG: 16/18
(89%) (P = 0.38,
log rank)
After 1 year#:
Limited disease:
IG: 10/17
(59%)
CG: 11/15
(73%)
(P = 0.32, log
rank)
After induction
and consolidation
radiochemother-
apy (at approxi-
mately 6 months)
:
IG:18/41 (44%)
CG:17/39
(44%)
IG:23/41 (56%)
CG: 20/39
(51%)
n.r. (Admis-
sion for neutrope-
nia and sepsis)
Limited disease:
IG:
5/17 (29%) CG:
11/15 (73%)
After 1 year#: Ex-
tensive disease:
IG: 12/28
(43%)
CG: 15/28
(54%) (P = 0.49,
log rank)
After 1 year#:Ex-
tensive disease:
approximately 28
to 60 months ob-
servation time#:
IG: 8/23 (35%)
CG: 10/24
(42%)
(P = 0.49, log
rank)
Extensive disease:
IG: 12/24
(50%)
CG: 15/24
(63%)
Wara 1981 n.r. After 1 year#:
IG: 22/33
(67%)
CG: 25/42
(60%) (p<0.08)
n.r. n.r.
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Abbreviations: # survival rates extracted fromKaplan-Meier curves, § survival rates estimated frommedian survival times, CR: complete
remission, PR: partial remission, SD: stable disease, NC: no change, PD: progressive disease, n.r.: not reported
Table 3. Synthetic thymic peptides: survival, response, toxicity
Study Survival rates Tumour response Toxicity (no. of patients)
OS DFS CR PR Grade 3/4 neu-
tropenia
Grade 3/4 infec-
tion
Maio 2010 At 1 year:
IG1 (IFN Éž+1.6
mg thymosin α1)
: 39/97 (40%)
IG2 (IFN Éž+3.2
mg thymosin α1)
: 36/97 (37%)
IG3 (IFN Éž+6.4
mg thymosin α1)
: 45/98 (46%)
IG4 (3.2 mg thy-
mosin α1)*: 38/
99 (39%)
total IG (IG1-3):
120/292 (41%)
CG (IFN Éž):
33/97 (34%)
At 1 year#:
IG1: 4/97 (4%)
IG2: 10/97
(10%)
IG3: 3/98 (3%)
IG4*: 10/99
(10%)
total IG (IG1-3):
17/292 (5%)
CG: 0/97
Best response
within 12 months
(measured at var-
ious time points):
IG1: 2/97 (2%)
IG2: 3/97 (3%)
IG3: 2/98 (3%)
IG4*: 2/99 (2%)
total IG (IG1-3):
7/292 (2%)
CG: 0/97
IG1: 5/97 (5%)
IG2: 7/97 (7%)
IG3: 4/98 (4%)
IG4*: 10/99
(10%)
total IG (IG1-3):
16/292 (5%)
CG: 4/97 (4%)
n.r.
Cheng 2004 After a median
time of survival in
IG of 10months§:
IG: 9/18 (50%)
CG: 9/23 (39%)
At 1 year:
IG: 3/18 (17%)
CG: 3/23 (13%)
(n.s.)
n.r. n.r.
Gebbia 1994 n.r. n.r. n.r. (ANC<1,000/
mm² and
fever>38°C)
IG1
(thymopentin):
12/23
(52%) IG2 (thy-
mopentin+G-
CSF): 4/22
(18%)
IG1+IG2: 16/45
(36%)
CG1 (placebo):
18/28 (64%)
CG2 (G-CSF):
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Table 3. Synthetic thymic peptides: survival, response, toxicity (Continued)
5/23 (22%)
CG1+CG2: 23/
51 (45%)
Gish 2009 At 6 months
IG: 12/14 (86%)
CG: 7/11 (64%)
n.r. Best response
within 18 months
(measured at var-
ious time points):
IG: 0/14
CG: 0/11
IG: 2/14 (14%)
CG: 2/11 (18%)
n.r. (severe bacterial
infections)
IG: 0/14
CG: 4/11 (36%)
At 12 months
IG: 9/14 (64%)
CG: 7/11 (64%)
At 2 years
IG: 8/14 (57%)
CG: 5/11 (45%)
GISOT 1987 After 3 months
mean observation
time:
IG: 432/447
(97%)
CG:197/203
(97%)
(P = 0,068, chi²)
n.r. n.r. n.r.
Schulof 1985 After 1 year#:
IG1 (main-
tenance therapy):
8/15 (53%)
IG2
(loading dose): 4/
13 (31%)
CG: 1/13 (8%)
After 1 year#:
IG1: 3/15 (20%)
IG2: 4/13 (31%)
CG: 0/13
n.r. n.r.
Abbreviations: # survival rates extracted fromKaplan-Meier curves, § survival rates estimated frommedian survival times, * not included
in metaanalysis; CR: complete remission, PR: partial remission, SD: stable disease, NC: no change, PD: progressive disease
Tumour response
Seventeen studies reported on tumour response and 14 of them
referred to defined response criteria mostly in accordance with
standard criteria. In Iaffaioli 1994 tumour response data were not
reported but the author summarised the results in the text. Pavesi
1993 reported data on an ’overall response rate’ but did not define
it any further and Sanchiz 1996 presented data on response refer-
ring to the first cycle of chemotherapy only (Table 2, Table 3).
Toxicity (adverse effects of chemotherapy and radiotherapy)
The two outcomes which were reported in a way that allowed us
to include them in our analyses were severe neutropenia and in-
fectious complications. Nine studies (Canovas 1991; Del Giacco
1988; Federico 1995; Gebbia 1994; Gish 2009; Iaffaioli 1988;
Macchiarini 1989; Sanchiz 1996; Scher 1988) reported on one or
both of these outcomes according to the National Cancer Insti-
tute Common Toxicity Criteria (CTC 2009) or gave a sufficient
description of the outcomes, which allowed us to apply grading
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criteria. Three of them reported on the incidence of grade 3 to 4
neutropenia per patient, one per chemotherapy cycle; and seven
on the incidence of grade 3 to 4 infectious complications (Table
2, Table 3).
Safety (adverse effects of purified thymus extracts (pTE) and
synthetic thymic peptides (sTP)
Ten trials commented on the ’tolerability’ of pTE or sTP (Bedikian
1984; Canovas 1988; Canovas 1991; Cohen 1979; Del Giacco
1988; Gebbia 1994; Gish 2009; Luzi 1984; Salvati 1984; Sanchiz
1996). The numbers of patients with local or systemic adverse
effects were given in three studies (Macchiarini 1989; Scher 1988;
Schulof 1985) (Table 4, Table 5).
Table 4. Purified thymus extract: safety
Study Adverse effects of purified thymus extracts
local systemic
Bedikian 1984 Erythema and induration of site of injection Generalized skin rash, febrile reaction
Canovas 1988 Authors stated that thymostimulin was well tolerated, but 2 patients were excluded because of allergic reaction
to TP-1
Canovas 1991 Authors stated that thymostimulin was well tolerated and no adverse reactions were observed
Cohen 1979 “Toxic effects of thymosin were confined to local irritation at the injection site manifested by greater or lesser
degrees of pain and swelling. All reactions subsided within 12-72 hours of injection.”
Del Giacco 1988 “No side effects were observed with thymostimulin,[...].”
Luzi 1984 “(...) no allergic reactions or toxic effects were noted during TS treatment.”
Macchiarini 1989 “No local or systemic thymostimulin-related clinical toxicities were noted.”
Salvati 1984 Authors stated that no toxic effects attributable to thymostimulin treatment were observed.
Sanchiz 1996 “(...) GCS-F and TS were well tolerated without adverse events related to these drugs.”
Scher 1988 Dose reduction because of local reactions (pain and
inflammation at injection site): 9/45 patients
chills and fever within 24 h of injection in 5/45 patients
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Table 5. Synthetic thymic peptides: safety
Study Adverse effects of synthetic thymic peptides
local systemic
Gebbia 1994 “Thymopentin treatment did not cause any significant side effects.”
Gish 2009 “Of the 23 adverse events the author judged possibly or probably related to thymalfasin, most were mild and resolved
without sequelae. Only three of these events occurred in more than one patient: nausea (n=2), fatigue (n=2), and
nipple pain (n=2).(...) Overall, thymalfasin was well tolerated.”
Schulof 1985 mild burning at the injection site in 3 patients. mild transient loss of muscle mass in1 patient.
Quality of life
None of the included studies reported on patient-reported QoL.
Excluded studies
Of the remaining 52 publications considered to be of possible rel-
evance, nine papers were duplicates and 17 did not fulfil inclusion
criteria. Reasons for exclusion of studies are described in the table
Characteristics of excluded studies.
Risk of bias in included studies
The quality of the included studies and the subsequent risk of bias
were assessed separately for the different outcomes of interest using
the criteria defined in the Cochrane Handbook (Higgins 2009).
The assessments and grades given are shown in Table 6 and Table
7. The studies are grouped below by the grades for risk of bias.
The grading is a basic judgement and does not account for the
complexity of many of the trials studied.
Table 6. Purified thymus extracts: risk of bias
Study Sequence
generation
Allocation
concealment
Blinding Attrition Selective
reporting
Risk of Bias
OS DFS/Tox
Airoldi 1987 Quote: ”i pazi-
enti sono stati
stratificati (...)
prima di es-
sere random-
izzati al trat-
tamento (...)“
Comment: se-
quence gener-
ation not re-
ported; no ear-
lier re-
ports from the
same investi-
gators found
that clearly de-
scribe the use
of random se-
quences
Not reported;
prog-
nostic factors
similarly dis-
tributed
No blinding
reported
No drop-
outs or with-
drawals
Compre-
hensive report
of outcomes
moderate moderate -
high
15Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. Purified thymus extracts: risk of bias (Continued)
Bedikian
1984
Quote:
”Patients
(...) were ran-
domized (...).“
Comment: se-
quence gener-
ation not re-
ported
Probably not
done: no con-
cealment
reported, dis-
similarities in
baseline prog-
nostic factors
No blinding
reported
Quote: Three
of
49 thymosin
patients have
been excluded
from the sub-
sequent eval-
uation of re-
sponse
and survival of
the thymosin
group (...)
Com-
ment: differ-
ential loss
in comparison
groups, but
extent of pos-
sible bias un-
clear
No indication
for selective
reporting
moderate -
high
high
Canovas 1988 Quote:
”La asignación
de los
pacientes.....se
realizó me-
diante el sis-
tema de nu-
meros aleato-
rios.“ Com-
ment: proba-
bly done, ta-
ble of random
numbers used
Not reported.
Equal
distribution of
characteris-
tics/prog-
nostic factors
stated
in text, but no
detailed data
provided
No blinding
reported
All patients
analysed
All
intended out-
comes were re-
ported
moderate moderate -
high
Canovas 1991 Quote: ” (...)
se realizó me-
diante la apli-
cación de la
tabla de nu-
meros
aleatorios (...)
.“ Comment:
probably
done, table of
random num-
bers used
Not reported.
Equal
distribution of
characteris-
tics/prog-
nostic factors
stated
in text, but no
detailed data
provided
No blinding
reported
All patients
analysed
All
intended out-
comes were re-
ported
moderate moderate -
high
16Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. Purified thymus extracts: risk of bias (Continued)
Cohen 1979 Quote: ”
(...) randomly
received (...)“
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported. Dis-
similarities in
baseline char-
ac-
teristics; small
sample size
No blinding
reported
Quote:”Statis-
tical analysis
was also (...)
of 55 patients.
All results (..)
in the 46 pro-
tocol-el-
igible patients
were also sig-
nificant
for (...) 55 pa-
tients.“ Com-
ment: number
of
withdrawals/
drop-outs bal-
anced, reasons
for exclusions
described, PP
and ITT per-
formed
Compre-
hensive report
of outcomes
moderate moderate -
high
De Serdio
1997
Quote:
”Las tablas de
azar nos sum-
inistra-
tron (...) sigu-
iente esquema
de random-
ización (...)
“ Comment:
adequate se-
quence gener-
ation
No
concealment
reported. De-
tailed list
of disease lo-
calisation and
stage given;
other patient
related charac-
teristics not re-
ported
No blinding
reported
All patients
analysed
All
intended out-
comes were re-
ported
Outcomes not
assessed
moderate -
high
Del Giacco
1988
Quote:” (...)
patients were
randomised
between (...)“
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported.
No blinding
reported
Quote: ”31
could be ran-
domised (...)
but only 22
are completely
evaluable (the
other 9 having
an incomplete
follow-up (..)
“ Comment:
9 patients lost
to follow-up,
rea-
Discrep-
ancy between
intended and
reported out-
come
measures, re-
sults on qual-
ity of life were
not reported,
tu-
mour response
only reported
in the prelim-
high high
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Table 6. Purified thymus extracts: risk of bias (Continued)
sons not com-
mented, dis-
tribution be-
tween in-
tervention and
control group
unclear
inary publica-
tion
Federico 1995 Quote:
”(...) patients
were ran-
domised (...).“
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported. Dis-
similarities in
baseline prog-
nostic
factors, which
were discussed
by study au-
thors as possi-
bly having
influenced the
outcomes
No blinding
reported
Equal num-
bers of drop-
outs/exclu-
sions in both
groups
Compre-
hensive report
of outcomes
moderate -
high
high
Gonnelli
1995
Quote:
”(...) were ran-
domly
selected (...)“
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported.
No blinding
reported
4 patients in-
evaluable, 1 in
IG, 3 in CG,
reasons not
stated, ITT for
tu-
mour response
and rate of in-
fection
Intended out-
comes not
stated
Outcome not
assessed
high
Guzman 1988 Quote:
“(...) were ran-
domised.”
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported. No
data on distri-
bution of risk
factors
No blinding
reported
All patients
analysed
All
intended out-
comes were re-
ported
moderate -
high
high
Iaffaioli 1994 Quote:
”(...) and ran-
domised (...)“
Comment: se-
quence gener-
ation not re-
ported
No conceal-
ment re-
ported; prog-
nostic factors
similarly dis-
tributed
No blinding
reported
All patients
analysed
Intended out-
comes
were not com-
prehensively
reported
Outcome not
assessed
moderate
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Table 6. Purified thymus extracts: risk of bias (Continued)
Luzi 1984 Quote:
”(...) in a ran-
domized con-
trolled study;
(...)“
Comment: se-
quence gener-
ation not re-
ported
No conceal-
ment re-
ported. Slight
imbalances in
patient-
related factors.
Small sample
size. (direction
of possible risk
unclear)
No blinding
reported
Three patients
with adeno-
carcinoma
were excluded
afterwards for
unknown rea-
sons, (two in
IG and on in
CG)
Intended out-
comes
were not com-
prehensively
reported
moderate -
high
high
Macchiarini
1989
Quote: ”The
randomiza-
tion was per-
formed by as-
signing a pre-
random-
ized sequential
number
to each patient
(...)“ Com-
ment: proba-
bly done, ta-
ble of random
numbers used
No
concealment
reported. Dis-
similarities in
disease stage.
Small sample
size.(pos-
sible risk of
bias in favor of
the interven-
tion group)
No blinding
reported
Two patients
from the con-
trol group ex-
cluded be-
cause of death
within the first
2
weeks of treat-
ment; no ITT;
(possible risk
of bias con-
cerning
mortality out-
comes in favor
of the control
group)
All
intended out-
comes were re-
ported
high high
Mantovani
1988
Quote:”(...)
enrolled for
study and ran-
domized (...)“
Comment: se-
quence gener-
ation not re-
ported
No
concealment
reported. Dis-
similarities in
disease charac-
teristics. Small
sam-
ple size.(pos-
sible risk of
bias in favour
of the control
group)
No blinding
reported
All patients
analysed
All
intended out-
comes were re-
ported
high high
Mustacchi
1994
Quote:
”(...) entering
this prospec-
tive random-
ized multicen-
ter trial (...)
“Comment:
sequence gen-
Quote:
”(...) were ran-
domly allo-
cated over the
phone by the
Central Office
(...)“Com-
ment: proba-
No blinding
reported
Quote: ”(...)
25
out of 235 pa-
tients were lost
due to cancel-
lation, ineligi-
bility or proto-
All intended
outcomes re-
ported
low - moder-
ate
moderate
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Table 6. Purified thymus extracts: risk of bias (Continued)
eration not re-
ported
bly done (cen-
tral allocation)
col violations
(..)“Com-
ment: dis-
tribution be-
tween groups
similar, out-
come measure
not likely to be
influenced
Pavesi 1993 Quote: ”(...)
and randomly
allocated (...)
“Comment:
sequence gen-
eration not re-
ported
Quote: ”(...)
and randomly
allocated over
the phone (...)
“Com-
ment: proba-
bly done (cen-
tral allocation)
No blinding
reported
Quote:
”(...) in 245
fully evaluable
patients (..)
“Com-
ment: 51 ran-
domised pa-
tients not in-
cluded in anal-
y-
sis, reasons not
reported, dis-
tribution be-
tween groups
unclear
Intended out-
comes were
reported (only
abstract pub-
lication avail-
able)
moderate moderate -
high
Salvati 1984 “(?) hanno
ricevuto a ran-
dom (?)
”Comment:
sequence gen-
eration not re-
ported
No conceal-
ment re-
ported. Distri-
bution of pos-
sible risk fac-
tors/dis-
ease character-
istics unclear.
Small sample
size
No blinding
reported
Quote:
”I pazienti va-
lutabili
sono stati 40
(..)“Com-
ment: six pa-
tients not in-
cluded in anal-
y-
sis, reasons not
reported, dis-
tribution be-
tween groups
unclear
Intended out-
comes were re-
ported (but re-
port was not
very detailed)
high high
Sanchiz 1996 Quote:
”(...) were ran-
domly
assigned
(by means of
tables of ran-
dom
numbers) (...)
“Com-
No conceal-
ment re-
ported. Slight
imbalances
in possible risk
factors/
disease charac-
teristics. Small
sample size
No blinding
reported
No dropouts/
withdrawals
reported but
unclear
whether all pa-
tients were in-
cluded in the
analyses
All
intended out-
comes were re-
ported
Outcome not
assessed
moderate -
high
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Table 6. Purified thymus extracts: risk of bias (Continued)
ment: proba-
bly done, ta-
ble of random
numbers used
Scher 1988 Quote: ”Ran-
dom-
ization was by
the method of
random per-
muted blocks
(...)“Com-
ment: proba-
bly done
No
concealment
reported. Dis-
similarities in
prognos-
tic factors be-
tween groups
No blinding
reported
All ran-
domised pa-
tients were in-
cluded in the
survival analy-
sis and the rea-
sons for the ex-
clusion
of three pa-
tients from the
response anal-
ysis were re-
ported and
unlikely to in-
troduce bias
Outcomes
comprehen-
sively reported
low - moder-
ate
moderate
Wara 1981 Quote:
“(?) were ran-
domly
assigned (?)
”Comment:
sequence gen-
eration not re-
ported
No
concealment
reported. Dis-
similar-
ities in prog-
nostic factors.
No blinding
reported
All but one
randomised
patients in-
cluded in the
analyses, rea-
son for exclu-
sion not re-
ported
All intended
outcomes re-
ported
Outcome not
assessed
moderate -
high
Table 7. Synthetic thymic peptides: risk of bias
Study Sequence
generation
Allocation
concealment
Blinding Attrition Selective
reporting
Risk of Bias
OS DFS/Tox
Cheng 2004 Quote:
“(...) were ran-
domly divided
(...) based on
the date
of admission.”
Comment:
Quasi-ran-
domisation
Prob-
ably not done;
study authors
did not use ad-
equate se-
quence gener-
a-
tion and base-
line prognos-
tic factors dis-
similarly dis-
tributed.
No blinding
reported
All patients
analysed.
All
intended out-
comes were re-
ported.
high high
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Table 7. Synthetic thymic peptides: risk of bias (Continued)
Gebbia 1994 Quote:
“(...) were ran-
domised (...)”
Comment: se-
quence gener-
ation not re-
ported
Not reported.
Similar distri-
bution of age,
gender, per-
formance sta-
tus, but no
data on site
of primary tu-
mour for the
placebo group
No blinding
reported
Quote: “(...) 4
patients were
excluded from
final analysis
due to major
protocol vio-
lation.” Com-
ment: unclear
distribution of
drop-outs be-
tween groups
Incomplete re-
port-
ing of hema-
tological and
infectious out-
comes
Outcome not
assessed
moderate -
high
Gish 2009 Quote: “Ran-
domiza-
tion was car-
ried out cen-
trally using a
ran-
domization ta-
ble (...)” Com-
ment: proba-
bly done, ta-
ble of random
numbers used
Quote: “Ran-
domiza-
tion was car-
ried out cen-
trally using a
ran-
domization ta-
ble (...)” Com-
ment: proba-
bly done (cen-
tral allocation)
Quote:
“tumour mea-
surements and
interpre-
tation (...) per-
formed
centrally by ra-
diol-
ogists blinded
to treatment
assignment
28
randomised,
25 treated and
eval-
uated, 3 with-
drawals in CG
before begin-
ning of treat-
ment
All intended
outcomes re-
ported
low - moder-
ate
low - moder-
ate
GISOT 1987 Quote:”
(...) per mezzo
di una lista
di randomiz-
zazione;“
Com-
ment: proba-
bly done, ta-
ble of random
numbers used
Not reported.
No
data on char-
acteristics/ risk
factors
No blinding
reported
Inconsis-
tent numbers
of drop-outs/
withdrawals
All
intended out-
comes were re-
ported
moderate moderate -
high
Maio 2010 Quote:
”The random-
ization list was
pro-
duced by the
Internal Qual-
ityControl
Unit of Bio-
statistics and
Data Manage-
ment (...)“
Comment:
adequate se-
Quote: ”Ran-
domization
was blinded
and central-
ized (...).
Com-
ment: proba-
bly done (cen-
tral allocation)
Quote: “tu-
mour response
was eval-
uated (...) uti-
lizing a central
review.”
Comment: al-
though central
review per-
formed, un-
clear whether
assessor was
For tumour
response all
patients were
analyzed, au-
thors assumed
that this was
the case for
the outcomes
OS and PFS as
well
Compre-
hensive report
of outcomes
low low - moder-
ate
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Table 7. Synthetic thymic peptides: risk of bias (Continued)
quence gener-
ation
blinded
Schulof 1985 Quote:
“(...) was per-
formed using
a randomized,
double-blind
design (...)
”Comment:
sequence gen-
eration not re-
ported
No
concealment
reported. Dis-
similarities in
prognos-
tic factors be-
tween groups
(possibly
in favour of in-
tervention
group). Small
sample size
Quote: “The
code did not
have to be bro-
ken because of
toxicity in any
patient (...)
”Comment:
Successful
blinding of pa-
tients and care
provider likely
Quote: “(...)
and adminis-
tered (...) for
a period of
up to 1 year
or until re-
lapse.”Comment:
Outcome
was assessed
during the
blinded study
phase in the
majority of
patients
All but one
randomised
patients in-
cluded in the
analyses, rea-
son for exclu-
sion reported
All intended
outcomes re-
ported
moderate moderate
Mortality outcomes
Studies with pTE were judged as having the following risk of bias
concerning OS:
• low to moderate: Mustacchi 1994; Scher 1988,
• moderate: Airoldi 1987; Canovas 1988; Canovas 1991;
Cohen 1979; Pavesi 1993,
• moderate to high: Bedikian 1984; Federico 1995; Guzman
1988; Luzi 1984,
• high: Del Giacco 1988; Macchiarini 1989; Mantovani
1988; Salvati 1984.
Studies with sTP were judged as having the following risk of bias
concerning OS:
• low: Maio 2010,
• low to moderate: Gish 2009,
• moderate: GISOT 1987; Schulof 1985,
• high: Cheng 2004.
Outcome assessor-related outcomes
Studies with pTE were judged as having the following risk of bias
concerning DFS and toxicity outcomes:
• moderate: Iaffaioli 1994,
• moderate to high: Airoldi 1987; Canovas 1988; Canovas
1991; Cohen 1979; De Serdio 1997; Gebbia 1994; Mustacchi
1994; Pavesi 1993; Sanchiz 1996; Scher 1988; Wara 1981,
• high: Bedikian 1984; Del Giacco 1988; Federico 1995;
Gonnelli 1995; Guzman 1988; Luzi 1984; Macchiarini 1989;
Mantovani 1988; Salvati 1984.
Studies with sTP were judged as having the following risk of bias
concerning DFS and toxicity outcomes:
• low to moderate: Gish 2009; Maio 2010,
• moderate: Schulof 1985,
• moderate to high: GISOT 1987,
• high: Cheng 2004.
Overall, the reasons for higher grades of risk of bias were due to
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inadequate reporting of the methods used for random allocation,
unbalanced risk factors for the outcome of interest and small sam-
ple sizes. For outcome assessor-related outcomes, inadequate re-
porting of the methods used for blinding were an additional rea-
son for assuming higher risk of bias.
Effects of interventions
Survival
Overall survival (OS)
Purified thymus extracts (pTE)
Fifteen trials with pTE reported OS data with observation periods
ranging from three to over 60 months. Data for meta-analysis of
OS at one year could be obtained from eight trials. The analysis
included a total of 705 patients and 355 events and the RR did
not show a difference in the risk of survival between the thymic
peptides regimen and no treatment or placebo (RR 1.00, 95% CI
0.79 to 1.25) (Analysis 1.1). Heterogeneity was moderate (I² =
44%).
Subgroup analysis
The thymostimulin group included five trials with 469 patients
and the thymosin fraction 5 group had three trials including 236
patients. In the thymostimulin group, the pooled RR was above 1
(RR 1.07, 95%CI 0.85 to 1.35), whereas in the thymosin fraction
5 group the RR was 0.84 (95% CI 0.49 to 1.45).
Synthetic thymic peptides (sTP)
Five trials with sTP reported OS data with observation periods
from three months to two years. Data for meta-analysis of OS at
one year could be obtained from four trials (Cheng 2004; Gish
2009;Maio 2010; Schulof 1985). All four trials used thymosinα1.
The analysis included 496 patients and 200 events. The RR for
OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14) without statistical
heterogeneity (I² = 0%).
Disease-free survival (DFS)
Purified thymus extracts (pTE)
Twelve trialswith pTE reportedDFSdatawith observationperiods
ranging from three to over 60 months. Data for meta-analysis of
DFS at one year could be obtained from six trials (Cohen 1979;
Federico 1995; Mantovani 1988; Pavesi 1993; Scher 1988; Wara
1981). The DFS analysis included a total of 511 patients and
308 events. The RR did not show a difference in the risk of DFS
between the thymic peptides regimen and no treatment or placebo
(RR 0.97, 95% CI 0.82 to 1.16) (Analysis 1.2). Heterogeneity
was moderate (I² = 30%).
Subgroup analysis
The thymostimulin group included three trials with 385 patients
and the thymosin fraction 5 group had three trials including 126
patients. The subgroup analysis showed no difference between the
two subgroups (thymostimulin: RR 0.93, 95% CI 0.73 to 1.19;
thymosin fraction 5: RR 1.06, 95% CI 0.71 to 1.60).
Synthetic thymic peptides (sTP)
Data were obtained for meta-analysis of DFS at one year from
three trials. All trials used thymosin α1. A total of 471 patients
with 30 events were included in analysis. The RR was 3.37 (95%
CI 0.66 to 17.30, P = 0.15) with moderate heterogeneity (I² =
37%) (Analysis 2.2).
Tumour response
Purified thymus extracts (pTE)
Data could be obtained for response analysis from 11 trials with
pTE. A total of 825 patients with 423 events were included in the
analysis. There was no difference in the overall chance of achieving
a complete or partial response between the intervention and the
control groups (RR 1.07, 95% CI 0.92 to 1.25) (Analysis 1.3).
Heterogeneity among the trials was rather high (I² = 53%).
Subgroup analysis
The thymostimulin group included eight trials with 553 patients
and 258 events; the thymosin fraction 5 group had three trials
including 225 patients with 131 events.
The pooled RR of trials using thymostimulin was 1.25 (95% CI
0.96 to 1.62, P = 0.09), whereas in the thymosin fraction 5 group
the RR was below 1 (RR 0.73, 95% CI 0.24 to 2.19, P = 0.57).
Synthetic thymic peptides (sTP)
Only two trials with thymosin α1 reported data on tumour re-
sponse (Gish 2009; Maio 2010). Therefore we did not pool data.
Both trials showed no significant difference between the interven-
tion and the control groups (RR 0.79, 95% CI 0.13 to 4.72; RR
1.91, 95% CI 0.68 to 5.39 respectively) (Analysis 2.3).
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Sensitivity analyses
Sensitivity analyses were performed using data from treatment
arms with higher doses of thymic peptides (Cohen 1979; Maio
2010) or maintenance regime instead of the loading dose (Schulof
1985). Overall, no significant changes were found in risks for sur-
vival and tumour response and in statistical heterogeneity. Details
are shown in Table 8.
Table 8. Sensitivity analyses
Purified thymus extracts - overall survival
Outcome Random effects model Single intervention groups in studies
with more doses/regimes tested
pTE RR 1.00, 95% CI 0.79 to 1.25, P = 0.98,
I²=44%
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.02, 95% CI 0.80 to 1.31, P = 0.87,
I²=52%
Thymostimulin (subgroup) RR 1.07, 95% CI 0.85 to 1.35, P = 0.57,
I²=35%
not applicable
Thymosin fraction 5 (subgroup) RR 0.84, 95% CI 0.49 to 1.45, P = 0.53,
I²= 48%
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.95, 95% CI 0.46 to 1.95, P = 0.89,
I²=69%
Purified thymus extracts - disease-free survival
pTE RR 0.97, 95% CI 0.82 to 1.16, P = 0.77,
I²= 30%
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.97, 95% CI 0.82 to 1.16, P = 0.78,
I²=32%
Thymostimulin (subgroup) RR 0.93, 95% CI 0.73 to 1.19, P = 0.59,
I²= 54%
not applicable
Thymosin fraction 5 (subgroup) RR 1.06, 95% CI 0.71 to 1.60, P = 0.76,
I²= 38%
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.07, 95% CI 0.70 to 1.64, P = 0.48,
I²=41%
Purified thymus extracts - tumour response
pTE RR 1.07, 95% CI 0.92 to 1.25, P = 0.37,
I²= 53%
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.04, 95% CI 0.89 to 1.21, P = 0.64,
I²=56%
Thymostimulin (subgroup) RR 1.25, 95% CI 0.96 to 1.62, P = 0.09,
I²=66%
not applicable
Thymosin fraction 5 (subgroup) RR 0.73, 95% CI 0.24 to 2.19, P = 0.57,
I²=94%
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.81, 95% CI 0.32 to 2.07, P = 0.65,
I²=92%
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Table 8. Sensitivity analyses (Continued)
Synthetic thymic peptides - overall survival
sTP RR 1.21, 95% CI 0.94 to 1.56, P = 0.14,
I²=0%
6.4 mg thymosin α1(Maio 2010) and
maintenance regime (Schulof 1985)
RR 1.30, 95% CI 0.92 to 1.85, P = 0.14,
I²=23%
Synthetic thymic peptides - disease-free survival
sTP RR 3.37, 95% CI 0.66 to 17.30, P = 0.15,
I²= 37%
6.4 mg thymosin α1 (Maio 2010) and
maintenance regime (Schulof 1985)
RR 2.22, 95% CI 0.67 to 7.37, P = 0.19,
I²=0%
Toxicity
Purified thymus extracts (pTE)
Infectious complications
Data could be obtained from four studies for pooled analysis of
severe infections (at least CTC grade 3 or 4). Three investigated
thymostimulin and one thymosin fraction 5. A total of 214 pa-
tients were included and 73 experienced a severe infectious com-
plication at any site. The RR indicated a lower risk of severe infec-
tious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008)
(Analysis 1.4). Heterogeneity among the trials was low (I² = 0%).
Neutropenia
Data for analysis of severe neutropenia (at least CTC grade 3 or 4)
could be obtained from three trials, which all used thymostimulin.
Overall, 72 of 149 patients experienced severe neutropenia. The
RR was 0.55 (95% CI 0.25 to 1.23, P = 0.15) (Analysis 1.5) with
high heterogeneity among the trials (I² = 63%).
Synthetic thymic peptides (sTP)
Only two trials with sTP reported data on infectious complica-
tions or neutropenia (Table 3). Therefore pooling of data was not
feasible. Gebbia 1994 found a non-significant reduction in the
number of patients experiencing neutropenia during chemother-
apy by treatment with thymopentin. Gish 2009 reported a non-
significant reduction in the rate of patients with severe bacterial
infections by treatment with thymosin α1.
Safety
Ten out of 20 studies with pTE and three out of six trials with
sTP reported on adverse effects of the interventional treatments.
Seven authors reported that the interventional treatments were
well tolerated. Adverse events reported by the other authors were
mild, transient local reactions at the injection site with systemic
reactions in few patients. Details are shown in Table 4 and Table
5.
D I S C U S S I O N
This review included data from26 trials (2736 patients) investigat-
ing the treatment of various malignancies with pTE or sTP while
receiving basic oncologic treatment consisting of chemotherapy
alone or in combination with radiotherapy or immunotherapy,
chemotherapy applied as transcatheter arterial embolization, or
radiotherapy alone. These 26 studies included both published and
unpublished trials and represented all RCTs matching the inclu-
sion criteria at the time of the literature search. The last trial was
identified in March 2010. Twenty studies used one of two pTE,
thymostimulin or thymosin fraction 5, and six one of two sTP,
thymopentin or thymosin α1, as investigational treatments.
We did not find evidence that the addition of pTE or sTP to
antineoplastic treatment reduces the risk of death or disease pro-
gression, nor that it improves the rate of tumour response to an-
tineoplastic treatment. However, there was preliminary evidence
that pTE lowered the risk of severe infectious complications in
patients undergoing chemotherapy or radiotherapy. There was no
evidence of significant side effects either with pTE or sTP.
The pTE was used to treat 1436 patients, and 372 breast can-
cer patients from three studies was the largest group. There were
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1300 participants treated with sTP, 488 patients with metastasised
melanoma were from one study. There were sufficient numbers
to assess treatment impact of both pTE and sTP on survival out-
comes, and of pTE on tumour response. There were only a few
trials with small numbers of patients that assessed the effects of
pTE and sTP on adverse effects of chemotherapy or radiotherapy
scored according to standardized criteria (CTC), therefore the tri-
als in this review have low power to assess the impact of the inter-
vention on this outcome. We had planned to perform subgroup
analyses with respect to different types of cancer. After appraisal of
the included studies, however, subgroup analysis was only possible
for the different investigational drugs applied.
Other major problems for this review were the poor methodolog-
ical quality of many of the included trials, variability in entry cri-
teria, the nature and timing of outcomes, and poor reporting of
both outcomes and methodology. In particular, there is a possibil-
ity of bias due to different treatment schedules and doses of both
the investigational and the basic oncologic treatments across the
trials, as well as a general failure to report data suitable for com-
parison of survival over time. Only four trials reported adequate
methods of allocation concealment, which could have introduced
bias. None of the trials with pTE and only one with sTP reported
blinding of outcome assessors, which could have introduced bias
in the assessment of DFS, tumour response and toxicity outcomes.
Another limitation of this systematic review was the small sample
size of many of the trials. In particular, two thirds of trials had
a sample size of less than 60 participants and may have yielded
inconclusive results because they were small and therefore did not
have adequate statistical power. Only six trials included more than
100 participants.
The included trials were published over a 31-year period, up to
2010, and mainly involved participants from Italy, Spain and the
USA. Studies with pTE were conducted from 1979 until the late
1990s. Thereafter this treatment concept was seemingly aban-
doned and clinical investigations became orientated towards the
application of sTP. All studies (n = 3) which were conducted after
1997 used the sTP thymosin α1.
Pooling of data was possible for a number of clinical outcomes
of interest. For thymosin α1 there was a slight trend toward an
overall reduction in the risk of dying (RR 1.21, 95% CI 0.94 to
1.56, P = 0.14) and improved DFS (RR 3.37, 95% CI 0.66 to
17.30, P = 0.15). Data from one large trial with low risk of bias on
patients with metastatic melanoma mainly contributed to these
results. Two trials with thymosin α1 compared either different
doses (Maio 2010) or different regimes of application (Schulof
1985). Results from these individual studies indicated a possible
dose-dependent effect. A further finding fromMaio’s trial that was
not included in our analysis but which could be of interest was
that thymosin α1 added to chemotherapy seemed to be as effective
as interferon α but better tolerated.
The different RR for tumour response of thymostimulin (above 1)
and thymosin fraction 5 (below 1) might be regarded as a possible
indicationof differential effects of the twodifferent pTE.However,
such an interpretation should be made with caution because the
suggested negative effect of thymosin fraction 5 is mainly caused
by one study at high risk of selection bias that involved patients
with advanced non-small cell lung cancer (Bedikian 1984). Never-
theless, true opposite effects of different pTE, for instance caused
by differences in the peptide composition, could not be ruled out
based on our data. Thymostimulin and thymosin fraction 5 have
dissimilar manufacturing processes and while there were little to
no efforts to analyse the components of thymostimulin, those
of thymosin fraction 5 came under scrutiny. One oligopeptide
identified from the thymosin fraction 5 is thymosin ß4, which
was recently discussed due to its possible stimulating effects on
tumour metastasis by activating cell migration and angiogenesis
(Cha 2003). The heterogeneity within the two groups might also
be attributable to different reactions of the various cancer entities
to pTE. Lack of sufficient studies with the same disease conditions
hampers further evaluation of this aspect.
Pooled estimates of trials of pTE suggest an advantage on the risk
of experiencing serious infectious complications or, as a trend, se-
vere neutropenia during basic oncological treatment. Two trials
with sTP reported similar findings on these outcomes but were
not included in the meta-analysis (Gebbia 1994; Gish 2009). Two
of the four arms in Gebbia 1994 compared thymopentin with G-
CSF. Although there was some evidence that thymopentin might
reduce the risk of infections, G-CSF was significantly more effec-
tive (Gebbia 1994). Given the safety profile of sTP, they could still
be of investigational interest for this indication.
All of these findings are subject to a potential publication bias.
While we have made every effort to locate further unpublished
data, it remains possible that this review is subject to a positive
publication bias, with generally favourable trials more likely to
achieve reporting. For instance Schulof referred, in a systematic
review from1985, to one trial of thymosin fraction 5with negative
effects on tumour response where the information was obtained
by personal communication (Schulof 1985). We could not trace
a publication.
Only one systematic review on thymic peptides in cancer patients
has been published so far (Ernst 1997). The author addressed the
question of clinical effectiveness of ’thymus therapy’ in cancer pa-
tients and included 13 of 21 RCTs published between 1979 and
1996. Inclusion criteriawere similar to those used in our review but
additionally included oral thymus preparations as interventional
treatments and immunologic parameters as outcomes. There was
no tool for assessment of methodological quality and study results
were interpreted narratively. The author criticised the trials be-
cause of low methodological quality, small sample sizes, heteroge-
neous study populations and statistical shortcomings. The overall
conclusion saw no ’compelling’ evidence for the efficacy of thymus
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extracts but regarded some results as ’promising’ and deserving of
further investigation. This overall conclusion is in accordance with
the results of our review pertaining to the set of trials included in
Ernst’s review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Data provided by four small RCTs suggest that purified thymus
extracts (pTE)might reduce the risk of infectious complications in
patients undergoing chemotherapy or radiotherapy, or both. The
effect of synthetic thymic petides on the same outcome is only sup-
ported by weak evidence. Findings that thymosin α1 might have
beneficial effects on survival were mainly supported by one larger
study with low risk of bias of patients with metastatic melanoma.
Given the limited treatment options for this condition and the sa-
fety profile of thymosin α1, treatment with thymosin α1 could be
considered assuming that the decision about its use was based on
expert clinical judgement. This should be discussed with patients
before they give their consent and, where possible, patients should
be offered entry into well-designed clinical trials.
Implications for research
There is a case for well-designed randomised trials to assess the
possible value of the application of thymosin α1, suggested by one
large trial in patients with metastasised melanoma. Future trials
must employ up-to-date antineoplastic and supportive treatment
regimens in both arms; should take into account a possible dose-
dependent effect of thymosinα1, evaluate appropriate sample sizes
with power to detect expected differences and apply effective and
explicit blinding of treatment allocation. Examined outcomemea-
sures should include QoL measured with validated instruments
and careful elucidation of any adverse effects.
Clinical trials with purified thymus extracts should not be advo-
cated in the management of cancer until the exact compositions
of the extracts are scrutinized and components are identified that
might confer possible effects on host immunity and tumour biol-
ogy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Airoldi 1987
Methods Design: 2-arm parallel trial with a no-treatment control group; stratification by type of pretreatment, location and
grading of tumour, disease status (non-responsive or recurrent)
No of centres: 1
Recruitment and setting: Medical Clinic and Department of Radiotherapy, University of Turin, Italy
Recruitment period: 01/84-08/85
Observation period: median: 14 months, minimum: 11 months
Ethical approval: unclear
Participants No of patients: 48 randomised, 48 evaluated
Condition: squamous cell cancer of the oral cavity non-responsive or recurrent after conventional therapy with
surgery and/or irradiation
Demographics: men: 39, women: 9; mean age (range): 58 (37-71) years
Informed consent: unclear
Interventions Interventional treatment: thymostimulin, dose/schedule: 1 mg/kg/day i.m. starting 7 days before chemotherapy
treatment, thereafter 2x/week for 4 weeks and 1x/week until tumour progression
Control treatment: no treatment
Basic treatment: vincristine 1.2 mg/m² i.v. (d1), bleomycin 18 mg/m² i.m. (d1), methotrexate 30 mg/m² i.v. (d2);
every week for 8 weeks
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), other
Notes Outcomes: side effects of chemotherapy were not scored using standardized criteria
Bedikian 1984
Methods Design: 2-arm parallel trial with a no-treatment control group; stratification by histological type of disease and
performance status
No of centers: 1
Recruitment and setting: M.D. Anderson Cancer Center, University of Texas, USA
Recruitment period: 01/79-05/80
Observation period: max. 104 weeks
Ethical approval: unclear
Participants No. of patients: 105 randomised, 99 evaluated
Condition: advanced stage non-small cell lung cancer (NSCLC)
Demographics: men: 70, women: 29; median age (range): IG: 55 (37-77), CG: 57 (35-80) years
Informed consent: yes
Interventions Interventional treatment: thymosin fraction 5; dose/schedule: 60 mg/m² s.c. every chemotherapy cycle
(d1,4,8,12,16)
Control treatment: no treatment
Basic treatment: vindesine 3 mg/m² (d1), doxorubicin 50 mg/m² (d1), cisplatin 60 mg/m² (d1) every 3-4 weeks
33Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bedikian 1984 (Continued)
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides),
chemotherapy dose/schedule modifications, other
Notes Participants: first 13 patients were not randomised because of unavailability of thymosin fraction 5 and allocated to
the no-treatment arm, thereafter to equalise the two arms a randomisation scheme favouring the thymosin arm was
used
Outcomes: side effects of chemotherapy were not scored using standardized criteria
Funding: sponsored by the National Cancer Institute (NCI)
Canovas 1988
Methods Design: 2-arm parallel trial with a no-treatment control group
No of centres: 1
Recruitment and setting: outpatients department, Hospital de Cruces, Bilbao, Spain
Recruitment period: unclear
Observation period: 4 chemotherapy cycles
Ethical approval: unclear
Participants No. of patients: 46 randomised, 41 evaluated
Condition: multiple myeloma (28 patients), non-Hodgkin lymphoma (NHL) (11 patients), Hodgkin lymphoma
(2 patients)
Demographics: unclear
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 25 mg i.m., 6x within 2 weeks at beginning of the study,
thereafter 4x within 2 weeks before each chemotherapy cycle
Control treatment: no treatment
Basic treatment: multiple myeloma: VCAP/VMCP, MP or M-2; NHL: Promace MOPP, CVP or CHOP; Hodgkin
lymphoma: MOPP/ABVD
Outcomes Outcome measures: survival, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides/extracts), other
Notes Outcomes: side effects of chemotherapy were not scored using standardized criteria; pre/post analysis of performance
status (ECOG)
Canovas 1991
Methods Design: 2-arm parallel trial with a no-treatment control group; patients stratified by diagnosis
No of centres: 1
Recruitment and setting: Hospital de Cruces, Bilbao, Spain
Recruitment period: unclear
Observation period: approximately 4-6 months (6 cycles of chemotherapy)
Ethical approval: unclear
Participants No. of patients: 40 randomised, 32 evaluated
Condition: multiple myeloma (13 patients), NHL (11 patients), Hodgkin lymphoma (8 patients)
Demographics: unclear
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Canovas 1991 (Continued)
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg body weight i.m., daily for one week; thereafter
2x/week for 6 chemotherapy cycles
Control treatment: no treatment
Basic treatment: multiple myeloma: VCAP/VMCP, MP or M-2; NHL: Promace MOPP, CVP, LSA2Ls, C-MOPP
or IMVP-16; Hodgkin lymphoma: MOPP MOPP/ABVD
Outcomes Outcome measures: survival, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Outcomes: side effects of chemotherapy were not scored using standardized criteria; pre/post analysis of performance
status (ECOG)
Cheng 2004
Methods Design: 3-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai,
China
Recruitment period: 01/00-12/02
Observation period: 6-32 months
Ethical approval: yes
Participants No. of patients: 57 for the whole trial, 41 randomised, 41 evaluated in the two relevant arms
Condition: hepatocellular carcinoma after hepatectomy; Edmondson´ s stage II-IV
Demographics: men: 34, women: 7; median age (range): 48 (30-66) years for whole study population
Informed consent: unclear
Interventions Interventional treatment: thymosin α1 (thymalfasin; Zadaxin) dose/schedule: 1.6 mg/day s.c., 2x/week from the
first week after hepatectomy for 6 months
Control treatment: no treatment
Basic treatment: transcatheter hepatic arterial chemoembolisation (TACE)with carboplatin: 100mg, epidoxorubicin
10 mg and mitomycin C 10 mg, starting 1.5 months after hepatectomy. In patients with recurrence, treatment was
repeated max. four times
Outcomes Outcome measures: survival
Notes Design: 2 arms were relevant for this review, the third arm compares transcatheter hepatic arterial chemoembolisation
with no treatment
Participants: imbalance in stage of disease, with a higher proportion of patients with stage IV in the intervention
group; distribution of patients with radical and palliative resection unclear
Funding: supported by Shanghai Science and Technology Committee and Shanghai Hospital New Star Plan
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Cohen 1979
Methods Design: 3-arm parallel with placebo control
No of centres: unclear
Recruitment and setting: NCI-VA Medical Oncology Branch, Veterans Administration Hospital, Washington,
D.C.; Surgery Branch, National Cancer Institute, Bethesda, USA
Recruitment period: 07/75-01/77
Observation period: approximately 2 years for survival, 12 weeks for response
Ethical approval: unclear
Participants No. of patients: 55 randomised, 46 evaluated
Condition: small cell lung cancer (SCLC), limited (15) or extensive (31) disease
Demographics:men: 34, women: 12; median age (range): IG1: 58 (49-69), IG2: 61 (47-69), CG: 53 (41-67) years
Informed consent: yes
Interventions Interventional treatment: thymosin fraction 5; dose/schedule: IG1: 60 mg/m² s.c., IG2: 20 mg/m² s.c., 2x/week
during induction chemotherapy
Control treatment: no treatment
Basic treatment: induction therapy: cyclophosphamide 1500 mg/m² (d1), lomustine 100 mg/m² (d1), cyclophos-
phamide 1000 mg/m² (d22), methotrexate 15 mg/m² 2x/week for 10 doses; maintenance therapy: cyclically alter-
nating two or three drug chemotherapy regimes for 2 years; starting on week 6
Outcomes Outcomemeasures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Participants: as stated by study authors patients in the IG2 tended to have a lower performance status
Outcomes: side effects of chemotherapy were not scored using standardized criteria
ITT analysis: was performed
Funding: thymosin fraction 5 was provided by Hoffmann-La Roche
De Serdio 1997
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: Hospital Nuestra SeÅŁora de la Cruz, Santa Cruz de Tenerife, Spain
Recruitment period: 03/93-09/95
Observation period: mean 18 months, max. 30 months
Ethical approval: unclear
Participants No. of patients: 36 randomised, 36 evaluated
Condition: locally advanced head and neck cancer, stage III or IV
Demographics: men: 35, women: 1; age (range): 30-66 years (no median given)
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 1.5 mg/kg/day i.m. for 7 days before radiochemotherapy,
1.5 mg/kg/day i.m. 2x/week during treatment, 1 mg/kg/day i.m. 2x/week for 2 years or until recurrence
Control treatment: no treatment
Basic treatment : radiochemotherapy with 1.15 Gy per fraction up to 80.5 Gy (cumultative dose), carboplatin 5
mg/m² per fraction up to 700 mg (cumulative dose); 2x/day, 5 days/week
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), other
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De Serdio 1997 (Continued)
Notes
Del Giacco 1988
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: Institute of Internal Medicine, University of Cagliari, Italy
Recruitment period: starting 01/81; duration unclear
Observation period: 12-33 months
Ethical approval: unclear
Participants No. of patients: 48 randomised, 48 evaluated (22 evaluated for tumour response)
Condition: NSCLC or SCLC after incomplete resection or unresectable, classified as immunodepressed by various
immunologic tests
Demographics (only reported in the preliminary publication for 22 patients): men: all patients; mean age (SD): IG:
58 (±8), CG: 57 (±11) years
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 1.5 mg/kg i.m. daily between cycles for 2 months; on
alternate days for 4 months; thereafter 2x/week
Control treatment: no treatment
Basic treatment: doxorubicin 50 mg/m² (d1), vincristine 1,2 mg/m² (d1), cyclophosphamide 400 mg/m² (d1),
lomustine 30 mg/m² (d1); every 4 weeks; until demonstrable response for max 6 cycles;
maintenance chemotherapy: NSCLC: cyclophosphamide 400 mg/m² (d1,d8), methotrexate 15 mg/m² (d1,d8),
procarbazine 100 mg/m² (d1-10); every 4 weeks; SCLC: cyclophosphamide 1000-1500 mg/m²; every 3 weeks,
methotrexate 10 mg/m² every 2 weeks, lomustine 50 mg/m² d1; thereafter VP16+adriamycin and methotrexate (no
exact description given by authors)
Outcomes Outcomemeasures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Various inconsistencies regarding inclusion criteria and dose of thymostimulin
Participants: in an earlier publication (1984) preliminary resultswere published on22patients 1 year after terminating
an enrolment phase of 21 months; patients with SCLC were not included at the beginning of the trial and inclusion
criteria were later changed
Interventions: there are differing doses stated in the two publications, the preliminary publication refers a dose of 1
mg/kg i.m.
Outcomes: side effects of chemotherapy were not scored using standardized criteria
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Federico 1995
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 6
Recruitment and setting: 2 university hospitals (Modena and Pavia) and 4 other hospitals in Italy
Recruitment period: 11/88-12/90
Observation period: 4 years, median follow up 38 months
Ethical approval: unclear
Participants No. of patients: 150 randomised, 134 evaluated
Condition: intermediate- or high-grade NHL, stage II-IV and stage I with bulky disease
Demographics: men: 73, women: 65 (mistake in publication); median age: IG: 52, CG: 51 years
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg i.m.; for pats. treated with MACOP-B: (d22-29,
50-57, 77-85), for pats. treated with ProMACE-CytaBOM (d22-28) of each chemotherapy cycle
Control treatment: no treatment
Basic treatment: comparative study of 2 chemotherapy regimes:
MACOP-B and ProMACE-CytaBOM: in both regimes doxorubicin was replaced by a 20% higher dose of epidox-
orubicin
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), other
Notes The study was designed by the Italian Lymphoma Study Group
Participants: performance status significantly better in IG (P = 0.04)
Funding: supported by public funding (MURST), the Associacione Italiana per la Ricerca sul Cancro (AIRC) and
Serono, Italy
Gebbia 1994
Methods Design: 4-arm parallel trial with placebo control
No. of centres: 1
Recruitment and setting: University of Palermo, Italy
Recruitment period: unclear
Observation period: unclear
Ethical approval: unclear
Participants No. of patients: 100 randomised, 96 evaluated (51 relevant to this review)
Condition: advanced breast cancer (26), advanced head and neck cancer (12), advanced gastric cancer (2), inoperable
ovarian cancer (4), recurrent or metastatic endometrium cancer (4), SCLC (6)
Demographics: women: 64, men: 36; mean age (range): 58.6 (40-75) years
Informed consent: yes
Interventions Interventional treatment: thymopentin; dose/schedule: 50mg i.m. every other day starting two days after application
of chemotherapy until the beginning of the next cycle
Control treatment: placebo (sodium chloride solution)
Basic treatment: breast cancer: 5-FU 400 mg/m² (d1-3), FA 100 mg/m² (d1-3), mitoxantrone 24 mg/m² (d3) or
5-FU 400 mg/m² (d1-3), FA 100 mg/m² (d1-3), cyclophosphamide 500 mg/m² (d1), epidoxorubicin 120 mg/m²
(d1); SCLC, head and neck cancer, endometrium cancer: cisplatin 80 mg/m²(d1), vinorelbine 25-30 mg/m² (d1,
d8); gastric cancer: according to EAP regime; ovarian cancer: carboplatin 300 mg/m² (d1), cyclophosphamide 500
mg/m² (d1), epidoxorubicin 90 mg/m² (d1)
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Gebbia 1994 (Continued)
Outcomes Outcome measures: toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides)
Notes
Gish 2009
Methods Design: 2-arm open-label trial with a no-treatment control group
No. of centres: 4
Recruitment and setting: California Pacific Medical Center, San Francisco; Henry Ford Health System, Detroit;
University of Florida College of Medicine, Gainesville; Metropolitan Liver and Gastroenterology Center Fairfax
Recruitment period: unclear
Observation period: 72 weeks (24 weeks treatment and 48 weeks post-treatment monitoring); 30 months for
survival
Ethical approval: unclear
Participants No. of patients: 28 randomised, 25 evaluated
Condition: unresectable HCC, stage I-III (Okuda),
Demographics: women: 6, men: 22; mean age (SD): IG: 59 (±9.1), CG: 60 (±6.7)
Informed consent: unclear
Interventions Interventional treatment: thymosin α1; dose/schedule: 1.6 mg s.c., 5x/week for 24 weeks
Control treatment: no treatment
Basic treatment: TACE with doxorubicin or cisplatin (according to participating site´ s guidelines)
Outcomes Outcomemeasures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Method: small pilot study, sample size calculation was performed based on tumour response, accordingly 18 patients
would have been required in each arm
Outcomes: side effects of chemotherapy were not scored using standardized criteria
Funding: supported by SciClone Pharmaceuticals
GISOT 1987
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 153
Recruitment and setting: inpatients of 153 hospitals, Italy
Recruitment period: unclear
Observation period: 3 months
Ethical approval: unclear
Participants No. of patients: 650 randomised, 609 evaluated
Condition: solid tumors
Demographics: unclear
Informed consent: unclear
Interventions Interventional treatment: thymopentin; dose/schedule: 50 mg s.c. 3x/week; for 4 weeks
Control treatment: no treatment
39Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GISOT 1987 (Continued)
Basic treatment: chemotherapy or radiotherapy (not further specified by the author)
Outcomes Outcome measures: survival, toxicity (AEs of chemo-/radiotherapy)
Notes Participants: the trial included in total three groups of patients at risk of infections: elderly people (> 65 years)
affected by chronic bronchitis (n=519), patients with solid tumours undergoing chemo- or radiotherapy (n=650),
patients with HIV infection and lymphoadenopathy syndrome (LAS) (n=250)
Outcomes: side effects of chemotherapy were not scored using standardized criteria
Gonnelli 1995
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: Institute of Internal Medicine and Division of Medical Oncology, University of Siena,
Italy
Recruitment period: unclear
Observation period: 6 months
Ethical approval: yes
Participants No. of patients: 40 randomised, 36 evaluated
Condition: breast cancer, patients with bone metastasis and at least one measurable osteolytic lesion
Demographics: median age (range): IG: 59 (47-71), CG: 61 (43-70) years
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 50 mg i.m. daily for 6 months
Control treatment: no treatment
Basic treatment: 5-fluoruracil 500 mg/m² (d1), epirubicin 50 mg/m² (d1), cyclophosphamide 500 mg/m² (d1), or:
5-fluoruracil 400 mg/m² (d1-5), folinic acid 200 mg/m² (d1-5); mitomycin C 5 mg/m² (d3-5); every 3 weeks
Outcomes Outcome measures: response, toxicity (AEs of chemo-/radiotherapy), other
Notes Method: according to a sample size calculation 60 patients would have been required, but accrual was finished earlier
due to loss of funding
Funding: thymostimulin was supplied by Serono, Italy
Guzman 1988
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: unclear
Recruitment and setting: Medical Institute Oncology Service and Guernes Center, Buenos Aires, Argentina
Recruitment period: 12/83-12/85
Observation period: up to 42 months
Ethical approval: unclear
Participants No. of patients: 32 randomised, 32 evaluated
Condition: colorectal cancer, Dukes B2, C1, C2 after surgery; colon cancer (29), rectal cancer (4)
Demographics: women: 15, men: 17; mean age: women: 58.8, men: 61.8 years
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Guzman 1988 (Continued)
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 25 mg/m² i.m. every chemotherapy cycle (d9-13,17,19,
24, 26)
Control treatment: no treatment
Basic treatment : 5-fluoruracil 600 mg/m² i.v. (d1,d8), lomustine 60 mg/m² p.o. (d1); every 3 weeks; for 6 months
Outcomes Outcome measures: survival, toxicity (AEs of chemo-/radiotherapy), other
Notes Participants: no reporting of distribution of risk factors between groups
Outcomes: side effects of chemotherapy were not scored using standardized criteria
Iaffaioli 1994
Methods Design: 2-arm parallel with placebo control
No. of centers: unclear
Recruitment and setting: unclear
Recruitment period: 04/89-02/92
Observation period: approximately 5 months
Ethical approval: yes
Participants No. of patients: 69 randomised, 69 evaluated
Condition: NSCLC, stage IIIA and B
Demographics: men: 51, women: 18; age: patients under or 65 years: 39, patients over 65 years: 30
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg; daily; after 2nd cycle: 3x/week, until end of
treatment
Control treatment: placebo (not further described)
Basic treatment: radiochemotherapy: 24 fractions of 1.60 Gy 2x/day up to 38.4 G, followed within 14 days by
one cycle of chemotherapy: carboplatin 250 mg/m² (d1), etoposide 100 mg/m² (d1), mitomycin C 8 mg/m² (d1-
3), followed within 14 days by radiotherapy: 12 fractions of 1.6 Gy 2x/day up to 19.2 Gy, thereafter 5 cycles of
chemotherapy
Outcomes Outcome measures: toxicity (AEs of chemo-/radiotherapy), other
Notes
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Luzi 1984
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: unclear
Recruitment period: unclear
Observation period: 2 years
Ethical approval: unclear
Participants No. of patients: 50 randomised, 47 evaluated
Condition: unresectable NSCLC, stage II or III
Demographics: men: 45, women: 5; mean age (range): 59 (35-70) years
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 0.5 mg/kg/day i.m. daily (starting 5 days before radio-
therapy); thereafter 1x/week for 6 months
Control treatment: no treatment
Basic treatment: 3 Gy on alternate days for 5 weeks; bleomycin 8 mg/m² 2x/week during radiotherapy, after 18
days: doxorubicin 40 mg/m² (d1, 28), vincristine 1.4 mg/m² (d1, 28), lomustine 65 mg/m² (d2, 57)
Outcomes Outcome measures: survival; response, other
Notes Funding: the trial was supported by a grant of the national research institute (Consiglio Nazionale delle Ricerche);
thymostimulin was supplied by Serono, Rome
Macchiarini 1989
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: unclear
Recruitment and setting: unclear
Recruitment period: 01/86-05/87
Observation period: up to 32 months; median 26.5 months
Ethical approval: unclear
Participants No. of patients: 28 randomised, 26 evaluated
Condition: SCLC limited (20) or extensive (6) disease
Demographics: men: 25, women: 1, median age: 61 years
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg/day i.m.; every chemotherapy cycle (d7-14);
thereafter in pats. with complete remission, 2x/week
Control treatment: no treatment
Basic treatment : cyclophosphamide 1 g/m² (d1), epidoxorubicin 60 mg/m² (d1), etoposide 120 mg/m² (d1-4), or:
cisplatin 60 mg/m² (d1), etoposide 120 mg/m² (d1-4); every 3-4 weeks, alternating the two regimes; for 6 cycles
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), other
Notes
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Maio 2010
Methods Design: open label 5-arm parallel, patients stratified by site of distant metastasis (M1a,b,c) and lactate dehydrogenase
(LDH) level
No of centres: 64
Recruitment and setting: multi-centre study across 8 European countries
Recruitment period: 08/02-01/06
Observation period: 14.9-56.5 months
Ethical approval: yes
Participants No. of patients: 488 patients evaluated (389 relevant to this review)
Condition: melanoma, stage IV without brain metastasis
Demographics: men: 250, women: 238
Informed consent: yes
Interventions Interventional treatment: thymosin α1; dose/schedule: IG1: 1.6 mg s.c.; IG2: 3.2 mg s.c. or IG3: 6.4 mg s.c. (d8-
11 and d15-18) of every chemotherapy cycle
Control treatment: no treatment
Basic treatment: dacarbazine 800 mg/m² i.v. every 4 weeks for a maximum of six cycles; interferon α (IFNα) 3MIU
s.c. (d11,18) of every chemotherapy cycle
Outcomes Outcomemeasures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Method: sample size calculation was performed, accordingly 95 patients would be required in each arm; the original
study design scheduled a four arm trial, but after preliminary analysis, which suggested a dose-response relation the
protocol was extended to integrate a fifth arm with a dose of thymosin α1 dose of 6.4 mg; sample size calculation
was performed, accordingly 95 patients would be required in each arm
Participants: only 4 of the 5 arms had a control group in accordance with the selection criteria of the review (the
other arm was controlled by IFNα)
Outcomes: AEs of thymic peptides not reported differentially; side effects of chemotherapy were not scored using
standardized criteria
Funding: supported by sigma-tau and SciClone Pharmaceuticals
Mantovani 1988
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 2
Recruitment and setting: university hospital and regional hospital, Cagliari, Italy
Recruitment period: unclear
Observation period: 1 (20 patients) or 2 years (16 patients)
Ethical approval: unclear
Participants No. of patients: 37 randomised, 37 evaluated
Condition: breast cancer, patients with positive axillary lymph nodes, after radical or modified radical mastectomy
Demographics: mean/median age (range): IG: 47.8/47.5 (31-60), CG: 45.8/47 (32-57) years
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 60 mg/m²/day i.m or s.c. starting within 1 month after
termination of chemotherapy: 7x/week (d1-15), 2x/week (d16-30), 1x/week (d31-60), repetition until d180 with a
pause of 30 days in-between
Control treatment: no treatment
43Thymic peptides for treatment of cancer patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mantovani 1988 (Continued)
Basic treatment : CMF regime; for 6 cycles
Outcomes Outcome measures: survival, toxicity (AEs of chemo-/radiotherapy), other
Notes Funding: supported by the National Research Council C.N.R.
Mustacchi 1994
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: multicentre
Recruitment and setting: various hospitals in Italy (Trieste, Pavia, Cagliari, Napoli, Sassari, Vigevano, Pinerolo,
Savona, Rome, Turin)
Recruitment period: 02/90-12/92
Observation period: unclear
Ethical approval: unclear
Participants No. of patients: 235 randomised, 211 evaluated
Condition: colorectal cancer stage IV
Demographics: men: 107, women: 128; median age: IG: 61, CG: 60 years
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg i.m.; daily during chemotherapy treatment, 3x/
week between cycles
Control treatment: no treatment
Basic treatment: 5-fluoruracil 375 mg/m² i.v. (60 min. infusion) (d1-5), folinic acid 200 mg/m² i.v. (60 min.
infusion) (d1-5); every 3 weeks
Outcomes Outcome measures: survival, response, safety (AEs of thymic peptides), other
Notes Method: sample size calculation was performed for incidence of side effects and tumour response and resulted in the
requirement of 130 patients per group
Outcomes: side effects of chemotherapy were not scored using standardized criteria
Pavesi 1993
Methods Design: 4-arm parallel (2 chemotherapy regimes) with no treatment control
No. of centres: 13
Recruitment and setting: 13 centres all over Italy
Recruitment period: 01/90-12/92
Observation period: unclear
Ethical approval: unclear
Participants No. of patients: 296 randomised, 245 evaluated
Condition: metastatic breast cancer (presumably stage IV)
Demographics: unclear
Informed consent: unclear
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Pavesi 1993 (Continued)
Interventions Interventional treatment: thymostimulin; dose/schedule: IG1/IG2: 1 mg/kg i.m. daily (during chemotherapy treat-
ment), thereafter 3x/week (until progression or withdrawal)
Control treatment: no additional treatment
Basic treatment: 5-fluoruracil 500 mg/m² i.v. (d1), epidoxorubicin 75 mg/m² i.v. (d1), cyclophosphamide 500 mg/
m² i.v. (d1); every three weeks or: folinic acid 200 mg/m² (d1-5), 5-fluoruracil 370 mg/m² (d1-5), epidoxorubicin
75 mg/m² (d1), cyclophosphamide 500 mg/m² (d1); every three weeks
Outcomes Outcome measures: survival; response, other
Notes This study has not been published in full text (February 2010) and was performed by the Italian Cooperative Trials
Group
Participants: unclear how many patients were allocated to which arm
Salvati 1984
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1 or 2
Recruitment and setting: Hospital C. Forlanini and Clinic of Respiratory Diseases, University of Rome, Italy
Recruitment period: unclear
Observation period: 6 months
Ethical approval: unclear
Participants No. of patients: 46 randomised, 40 evaluated
Condition: SCLC, limited (34) or extensive (12) disease
Demographics: men: 42, women: 4; median age (range): 57 (46-71) years
Informed consent: unclear
Interventions Interventional treatment: thymostimulin; dose/schedule: 1 mg/kg/day; 1st cycle (d4-10), 2nd-4th cycle (d4-6), 5th-
9th cycle (d4, 5)
Control treatment: no treatment
Basic treatment: methotrexate 40 mg/m² i.v. (d1), doxorubicin 40 mg/m² i.v. (d1), cyclophosphamide 400 mg/m²
i.v. (d1), nitrosourea 30 mg/m² i.v., (d1); every 3 weeks; for 6 months or until progression
Outcomes Outcome measures: survival, response, toxicity (AEs of chemo-/radiotherapy), other
Notes Participants: distribution of risk factors between groups not reported
Funding: thymostimulin supplied by Serono, Rome
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Sanchiz 1996
Methods Design: 2-arm parallel trial with a no-treatment control group
No. of centres: 1
Recruitment and setting: Department of Radiotherapy and Oncology, Clinica Platon, Barcelona, Spain
Recruitment period: 06/92-12/93
Observation period: one cycle of chemotherapy
Ethical approval: unclear
Participants No. of patients: 54 randomised, 54 evaluated
Condition: metastatic breast cancer
Demographics: median age (range): IG: 46 (38-54), CG: 46 (32-54) years
Informed consent: yes
Interventions Interventional treatment: thymostimulin; dose/schedule: 50 mg/day i.m.; every cycle (d2-16)
Control treatment: no treatment
Basic treatment: mitoxantrone 28 mg/m² i.v., supportive treatment: G-CSF 5 µg/kg s.c. (d2-16)
Outcomes Outcome measures: response, toxicity (AEs of chemo-/radiotherapy)
Notes
Scher 1988
Methods Design: 2-arm parallel trial with a no-treatment control group; patients stratified by performance status and disease
extent
No. of centres: 2
Recruitment and setting:Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York,
USA
Recruitment period: 05/79- 05/82
Observation period: approximately 25 to 60 months
Ethical approval: unclear
Participants No. of patients: 91 randomised, 80 evaluated
Condition: SCLC limited (32) or and extensive disease (48)
Demographics: men: 59, women: 32; median age (range): IG: 59 (35-73), CG: 53 (32-72) years
Informed consent: unclear
Interventions Interventional treatment: thymosin fraction 5; dose/schedule: 60 mg/m² s.c.; 2x/week from the start of induction
therapy through the completion of radiotherapy
Control treatment: no treatment
Basic treatment: induction therapy: 1st and 3rd cycle: cyclophosphamide 1200 mg/m² (d1), doxorubicin 50 mg/
m² (d1), vincristine 1.2 mg/m² (d1, 8); 2nd and 4th cycle: cisplatin 60 mg/m² (d1) and etoposide 120 mg/m²
(d4, 6, 8); consolidation therapy: cyclophosphamide 500 mg/m² (d1,14), vincristine 1,4 mg/m² (d1,14) along with
radiation therapy in patients with limited disease; maintenance therapy was started 10 weeks after completion of
radiotherapy in patients who had achieved complete remission, others started after hematologic recovery: 1st cycle:
lomustine 60 mg/m² p.o. (d1), methotrexate 30 mg/week for 4 weeks, procarbazine 100 mg/m² p.o. (d1-14); 2nd
cycle cyclophosphamide 1000 mg/m² (d42) and doxorubicin 30 mg/m²(d42); 3rd cycle: vincristine 1,2 mg/m² d63,
cisplatin 50 mg/m² d63 and etoposide 120 mg/m² (d67, 69, 71); radiotherapy with 2.5 Gy/day up to 45 Gy to
primary site and anterior mediastinum (patients with LD); 3 Gy/day up to 30 Gy whole brain radiation (all patients)
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Scher 1988 (Continued)
Outcomes Outcomemeasures: survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other
Notes Method: sample size calculation was performed, accordingly 80 patients would be required in order to detect a 25%
increase in complete remission rate
Funding: supported in part by the American Cancer Society and the National Institutes of Health (NIH); thymosin
fraction 5 was supplied by Hoffmann-La Roche
Schulof 1985
Methods Design: double blind 3-arm parallel with placebo control
No. of centres: 1
Recruitment and setting: Washington University Medical Center, Washington D.C., USA
Recruitment period: 11/80-01/83
Observation period: 1 year for relapse; all patients were followed up until death; median 40 weeks (8-108)
Ethical approval: unclear
Participants No. of patients: 42 randomised, 41 evaluated
Condition: locally advanced NSCLC, patients who had received radiotherapy because of either an unresectable
tumour or incomplete resection (R1 or R2); patients with progression under radiotherapy were not included
Demographics:men: 26, women: 15; mean age (SD): IG1: 57.3 (± 9.2), IG2: 52.8 (± 8.5), CG: 55.6 (± 10.5) years
Informed consent: yes
Interventions Interventional treatment: thymosin α1; dose/schedule: IG1: placebo daily for 14 days; thereafter 900 µg/m²/day
s.c., 2x/week as maintenance therapy; IG2: 900µg/m²/day, for 14 days as loading dose, thereafter placebo 2x/week
as maintenance therapy; administration was initiated one week after completion of radiotherapy for a period of up
to 1 year or until relapse
Control treatment: placebo (mannitol powder reconstituted in bicarbonate diluent, provided in same coded vials as
thymosin α1): daily for 14 days; maintenance therapy: 2x/week
Basic treatment: radiotherapy: 2 Gy/day 5x/week for 6-8 weeks to mediastinum and primary lesion, patients with
prior resection of tumour received irradiation only to mediastinum
Outcomes Outcome measures: survival, safety (AEs of thymic peptides), other
Notes Participants: imbalance in gender distribution and proportion of patients with resection of primary (IGs 11/28, CG
1/13) which was also discussed by the authors
Funding: supported by the National Cancer Institute (NCI) and Hoffmann-La Roche
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Wara 1981
Methods Design: open label 2-arm parallel
No. of centres: 1
Recruitment and setting:Department of RadiationOncology and Pediatrics, University of California, San Francisco,
USA
Recruitment period: 4 years before publication
Observation period: min. 8 months, median 2 years.
Ethical approval: unclear
Participants No. of patients: 76 randomised, 75 evaluated
Condition: squamous cell cancer of head and neck, stage II-IV
Demographics: unclear
Informed consent: unclear
Interventions Interventional treatment: thymosin fraction 5; dose/schedule: 60 mg/m²: daily for 10 days; thereafter 2x/week for
50 weeks
Control treatment: no treatment
Basic treatment: radiotherapy with 50-60 Gy
Outcomes Outcome measures: survival, other
Notes Interventions: thymosin fraction 5 was supplied by Hoffmann-La Roche
Outcomes which were not relevant to this review are indicated as ’other’. This includes immunologic parameters, dose modifications
of chemotherapy or radiotherapy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Azizi 1984 Patients received neither chemotherapy nor radiotherapy
Bernengo 1983 No sufficient outcome data reported
Cartia 1990 No sufficient outcome data reported
Chen 2000 Outcome assessment not according to eligibility criteria of the review
De Maria 1993 Only immune parameters reported
Denaro 1994 Only immune parameters reported
Holowiecki 1984 Not randomised for purified thymic extract
Iaffaioli 1988 Outcome assessment not according to eligibility criteria of the review
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Kreuser 1998 Registered randomised controlled trial, yet unpublished; manufacturer contacted, but no data provided
Liberati 1998 Only immune parameters reported
Mantovani 1995 Only immune parameters reported
Migeod 1985 Only immune parameters reported
Munno 1995 Only immune parameters reported
Quang-Xing 2001 Outcome assessment not according to eligibility criteria of the review
Shoham 1988 No concomitant chemotherapy or radiotherapy
Surico 1992 Outcome assessment not according to eligibility criteria of the review
Tetti 1987 Outcome assessment not according to eligibility criteria of the review
Characteristics of studies awaiting assessment [ordered by study ID]
Dollinger 2010
Methods Prospective randomised, placebo-controlled, double blind, multicentre clinical phase III trial
Participants 135 patients with locally advanced or metastasised HCC (Karnofsky >=60% - Child-Pugh <=12)
Interventions Thymostimulin 75mg s.c. 5x per week or placebo
Outcomes Primary endpoint was 12-month survival, secondary endpoints overall survival (OS), time to progression (TTP),
tumour response, safety and quality of life
Notes Current Controlled Trials ISRCTN64487365
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D A T A A N D A N A L Y S E S
Comparison 1. Purified thymus extracts versus no treatment or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 8 705 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.79, 1.25]
1.1 Thymostimulin 5 469 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.85, 1.35]
1.2 Thymosin fraction 5 3 236 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.49, 1.45]
2 Disease free survival 6 511 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.16]
2.1 Thymostimulin 3 385 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.73, 1.19]
2.2 Thymosin fraction 5 3 126 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.71, 1.60]
3 Tumour response 11 778 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.92, 1.25]
3.1 Thymostimulin 8 553 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.96, 1.62]
3.2 Thymosin fraction 5 3 225 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.24, 2.19]
4 Toxicity (patients with grade 3/4
infectious complications)
4 214 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.38, 0.78]
4.1 Thymostimulin 3 134 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.19, 0.75]
4.2 Thymosin fraction 5 1 80 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.41, 0.95]
5 Toxicity (patients with grade 3/4
neutropenia)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Thymostimulin 3 149 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.25, 1.23]
Comparison 2. Synthetic thymic peptides versus no treatment or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 4 496 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.94, 1.56]
1.1 Thymosin α1 4 496 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.94, 1.56]
2 Disease free survival 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Thymosin α1 3 471 Risk Ratio (M-H, Random, 95% CI) 3.37 [0.66, 17.30]
3 Tumour response 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Purified thymus extracts versus no treatment or placebo, Outcome 1 Overall
survival.
Review: Thymic peptides for treatment of cancer patients
Comparison: 1 Purified thymus extracts versus no treatment or placebo
Outcome: 1 Overall survival
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymostimulin
Airoldi 1987 12/24 10/24 9.7 % 1.20 [ 0.65, 2.23 ]
Federico 1995 51/66 48/68 27.6 % 1.09 [ 0.89, 1.34 ]
Luzi 1984 8/25 6/25 5.3 % 1.33 [ 0.54, 3.29 ]
Macchiarini 1989 10/15 2/11 2.8 % 3.67 [ 1.00, 13.50 ]
Mustacchi 1994 53/106 60/105 24.5 % 0.88 [ 0.68, 1.13 ]
Subtotal (95% CI) 236 233 69.9 % 1.07 [ 0.85, 1.35 ]
Total events: 134 (intervention), 126 (control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.18, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Thymosin fraction 5
Bedikian 1984 8/46 16/53 7.2 % 0.58 [ 0.27, 1.22 ]
Cohen 1979 12/30 3/16 3.7 % 2.13 [ 0.70, 6.47 ]
Scher 1988 23/45 31/46 19.2 % 0.76 [ 0.53, 1.08 ]
Subtotal (95% CI) 121 115 30.1 % 0.84 [ 0.49, 1.45 ]
Total events: 43 (intervention), 50 (control)
Heterogeneity: Tau2 = 0.12; Chi2 = 3.86, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 357 348 100.0 % 1.00 [ 0.79, 1.25 ]
Total events: 177 (intervention), 176 (control)
Heterogeneity: Tau2 = 0.04; Chi2 = 12.60, df = 7 (P = 0.08); I2 =44%
Test for overall effect: Z = 0.03 (P = 0.98)
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Analysis 1.2. Comparison 1 Purified thymus extracts versus no treatment or placebo, Outcome 2 Disease
free survival.
Review: Thymic peptides for treatment of cancer patients
Comparison: 1 Purified thymus extracts versus no treatment or placebo
Outcome: 2 Disease free survival
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymostimulin
Federico 1995 35/39 24/29 33.9 % 1.08 [ 0.89, 1.32 ]
Mantovani 1988 5/11 7/10 4.8 % 0.65 [ 0.30, 1.39 ]
Pavesi 1993 74/148 86/148 31.8 % 0.86 [ 0.70, 1.06 ]
Subtotal (95% CI) 198 187 70.5 % 0.93 [ 0.73, 1.19 ]
Total events: 114 (intervention), 117 (control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.35, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Thymosin fraction 5
Cohen 1979 7/11 2/8 1.8 % 2.55 [ 0.71, 9.16 ]
Scher 1988 10/17 11/15 10.0 % 0.80 [ 0.49, 1.32 ]
Wara 1981 22/33 25/42 17.7 % 1.12 [ 0.79, 1.58 ]
Subtotal (95% CI) 61 65 29.5 % 1.06 [ 0.71, 1.60 ]
Total events: 39 (intervention), 38 (control)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 259 252 100.0 % 0.97 [ 0.82, 1.16 ]
Total events: 153 (intervention), 155 (control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.15, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 0.30 (P = 0.77)
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Analysis 1.3. Comparison 1 Purified thymus extracts versus no treatment or placebo, Outcome 3 Tumour
response.
Review: Thymic peptides for treatment of cancer patients
Comparison: 1 Purified thymus extracts versus no treatment or placebo
Outcome: 3 Tumour response
Study or subgroup intervention control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymostimulin
Airoldi 1987 14/24 6/24 2.33 [ 1.08, 5.04 ]
De Serdio 1997 17/18 17/18 1.00 [ 0.85, 1.17 ]
Del Giacco 1988 0/10 0/12 0.0 [ 0.0, 0.0 ]
Federico 1995 53/66 51/68 1.07 [ 0.89, 1.28 ]
Gonnelli 1995 6/19 4/17 1.34 [ 0.45, 3.96 ]
Macchiarini 1989 11/15 4/11 2.02 [ 0.87, 4.67 ]
Mustacchi 1994 32/106 19/105 1.67 [ 1.01, 2.75 ]
Salvati 1984 12/20 12/20 1.00 [ 0.60, 1.66 ]
Subtotal (95% CI) 278 275 1.25 [ 0.96, 1.62 ]
Total events: 145 (intervention), 113 (control)
Heterogeneity: Tau2 = 0.06; Chi2 = 17.62, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.69 (P = 0.092)
2 Thymosin fraction 5
Bedikian 1984 10/46 24/53 0.48 [ 0.26, 0.90 ]
Cohen 1979 11/30 8/16 0.73 [ 0.37, 1.45 ]
Scher 1988 41/41 37/39 1.05 [ 0.97, 1.15 ]
Subtotal (95% CI) 117 108 0.73 [ 0.24, 2.19 ]
Total events: 62 (intervention), 69 (control)
Heterogeneity: Tau2 = 0.88; Chi2 = 33.14, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 395 383 1.07 [ 0.92, 1.25 ]
Total events: 207 (intervention), 182 (control)
Heterogeneity: Tau2 = 0.02; Chi2 = 19.07, df = 9 (P = 0.02); I2 =53%
Test for overall effect: Z = 0.90 (P = 0.37)
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Analysis 1.4. Comparison 1 Purified thymus extracts versus no treatment or placebo, Outcome 4 Toxicity
(patients with grade 3/4 infectious complications).
Review: Thymic peptides for treatment of cancer patients
Comparison: 1 Purified thymus extracts versus no treatment or placebo
Outcome: 4 Toxicity (patients with grade 3/4 infectious complications)
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymostimulin
Canovas 1991 2/16 4/16 5.4 % 0.50 [ 0.11, 2.35 ]
Del Giacco 1988 0/25 2/23 1.5 % 0.18 [ 0.01, 3.65 ]
Sanchiz 1996 6/27 16/27 21.8 % 0.38 [ 0.17, 0.81 ]
Subtotal (95% CI) 68 66 28.6 % 0.38 [ 0.19, 0.75 ]
Total events: 8 (intervention), 22 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Thymosin fraction 5
Scher 1988 17/41 26/39 71.4 % 0.62 [ 0.41, 0.95 ]
Subtotal (95% CI) 41 39 71.4 % 0.62 [ 0.41, 0.95 ]
Total events: 17 (intervention), 26 (control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Total (95% CI) 109 105 100.0 % 0.54 [ 0.38, 0.78 ]
Total events: 25 (intervention), 48 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.34 (P = 0.00082)
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Analysis 1.5. Comparison 1 Purified thymus extracts versus no treatment or placebo, Outcome 5 Toxicity
(patients with grade 3/4 neutropenia).
Review: Thymic peptides for treatment of cancer patients
Comparison: 1 Purified thymus extracts versus no treatment or placebo
Outcome: 5 Toxicity (patients with grade 3/4 neutropenia)
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymostimulin
Iaffaioli 1994 7/37 12/32 36.9 % 0.50 [ 0.23, 1.13 ]
Macchiarini 1989 0/15 4/11 7.1 % 0.08 [ 0.00, 1.40 ]
Sanchiz 1996 20/27 27/27 56.0 % 0.75 [ 0.59, 0.94 ]
0.01 0.1 1 10 100
Favours intervention Favours control
Analysis 2.1. Comparison 2 Synthetic thymic peptides versus no treatment or placebo, Outcome 1 Overall
survival.
Review: Thymic peptides for treatment of cancer patients
Comparison: 2 Synthetic thymic peptides versus no treatment or placebo
Outcome: 1 Overall survival
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymosin 1
Cheng 2004 9/18 9/23 13.5 % 1.28 [ 0.64, 2.54 ]
Gish 2009 9/14 7/11 18.1 % 1.01 [ 0.56, 1.83 ]
Maio 2010 120/292 33/97 66.7 % 1.21 [ 0.89, 1.65 ]
Schulof 1985 12/28 1/13 1.7 % 5.57 [ 0.81, 38.42 ]
Total (95% CI) 352 144 100.0 % 1.21 [ 0.94, 1.56 ]
Total events: 150 (intervention), 50 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
0.5 0.7 1 1.5 2
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Analysis 2.2. Comparison 2 Synthetic thymic peptides versus no treatment or placebo, Outcome 2 Disease
free survival.
Review: Thymic peptides for treatment of cancer patients
Comparison: 2 Synthetic thymic peptides versus no treatment or placebo
Outcome: 2 Disease free survival
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Thymosin 1
Cheng 2004 3/18 3/23 50.9 % 1.28 [ 0.29, 5.59 ]
Maio 2010 17/292 0/97 24.5 % 11.71 [ 0.71, 192.86 ]
Schulof 1985 7/28 0/13 24.6 % 7.24 [ 0.44, 117.98 ]
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Analysis 2.3. Comparison 2 Synthetic thymic peptides versus no treatment or placebo, Outcome 3 Tumour
response.
Review: Thymic peptides for treatment of cancer patients
Comparison: 2 Synthetic thymic peptides versus no treatment or placebo
Outcome: 3 Tumour response
Study or subgroup intervention control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Gish 2009 2/14 2/11 0.79 [ 0.13, 4.72 ]
Maio 2010 23/292 4/97 1.91 [ 0.68, 5.39 ]
0.01 0.1 1 10 100
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A P P E N D I C E S
Appendix 1. Glossary of terms
EORTC European Organization for Research and Treatment of Cancer
Breslow thickness Measuring of the depth of penetration of a melanoma into the skin in mm
Dukes Staging score for Colorectal cancer
WHO World Health Organization
RECIST Response Evaluation Criteria In Solid Tumors: a set of published rules that define when malignant tumours
respond (“respond”), stay the same (“stable”) or worsen (“progression”) during treatments
OS Overall survival: denotes the chances of staying alive for a group of individuals suffering from a cancer. It denotes
the percentage of individuals in the group who are likely to be alive after a particular duration of time
DFS Disease-free survival: denotes the chances of staying free of disease after a particular treatment for a group of
individuals suffering from a cancer. It is the percentage of individuals in the group who are likely to be free of
disease after a specified duration of time.
pTE Purified extracts from animal thymus glands containing peptide mixtures
sTP Synthetically produced single thymic peptides.
Appendix 2. Search strategies
PubMed - CENTRAL - MEDLINE
These databases were searched with 37 terms that referred to Thymyc/Peptide extracts.
Search terms used to identify interventions were:
1. Thymostimulin or thymoxtimulin
2. TF5
3. Thymosin
4. Thymosin fraction 5
5. Tα1 or Talpha1 or Thymosin alfa one or thymalfasin or zadaxin
6. Thymic serum factors
7. Tβ4 or thymosin beta four
8. Tγ or thymosin gamma
9. TFX or thymomodulin or thymic factor x or TFX-Polfa
10. TFX-Jelfa
11. TP-1
12. Thym-uvocal or Thymuvocal
13. Thymoject/thymojekt
14. Biosin
15. Thymex-L or thymex l
16. Thymophisin/Thymophysin
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17. Zellmedin-thymus or THX
18. Neytumourin Sol
19. NeyThymun
20. Thymuskin
21. Thymushydrolysate
22. Solcothymosin
23. Thymowied
24. Leucotrofina
25. FTS-Zn
26. Thymulin
27. Thymic serum factor
28. THFγ
29. Thymic humoral factor
30. HTH or Homeostatic thymic hormone
31. Thymopoietin (I and II) or TP5 or Thymopentin
32. Prothymosin α
33. Thymus peptide
34. LSH
35. Lymphocytopoietic factor
36. Wobe-Mugos
37. t-activin or tactivin
PubMed limits to identify the type of study:
• Humans
• Type of Article: Clinical Trial OR Meta-Analysis OR Randomized Controlled Trial OR Review
• More Publication Types: Clinical Trial, Phase I OR Clinical Trial, Phase II OR Clinical Trial, Phase III OR Clinical Trial, Phase
IV OR Controlled Clinical Trial OR Multicenter Study
• Topics: Cancer OR Complementary Medicine OR Systematic Reviews OR Toxicology
• Age : All Adult: 19+ years OR Young Adult: 19-24 years OR Adult: 19-44 years OR Middle Aged: 45-64 years OR Middle
Aged + Aged: 45+ years OR Aged: 65+ years80 and over: 80+ years
Example of search:
(“thymostimulin”[Substance Name] OR “thymostimulin”[All Fields])
AND
(“neoplasms”[MeSH Terms] OR “neoplasms”[All Fields] OR “cancer”[All Fields])
AND
(“humans”[MeSH Terms])
AND
(Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase
I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR Controlled Clinical
Trial[ptyp] OR Multicenter Study[ptyp])
AND
(cancer[sb] OR cam[sb] OR systematic[sb] OR tox[sb] ORmedline[sb] OR pubmed pmc local[sb]) AND (“adult”[MeSH Terms] OR
“young adult”[MeSH Terms] OR “adult”[MeSH Terms:noexp] OR “middle aged”[MeSH Terms] OR (“middle aged”[MeSH Terms]
OR “aged”[MeSH Terms]) OR “aged”[MeSH Terms] OR “aged, 80 and over”[MeSH Terms]))
EMBASE SEARCH:
The same 37 above mentioned PubMed terms were also searched in EMBASE.
EMBASE limits to identify the type of study:
• human
• article or “review”
• adult <18 to 64 years> or aged <65+ years>
• intramuscular or subcutaneous
Example of search:
Thymic extracts OR Thymus extracts OR Thymos* OR Thym*
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AND
Cancer).mp. [mp=title, abstract, subject headings, headingword, drug trade name, original title, devicemanufacturer, drugmanufacturer
name]
OTHER DATABASE SEARCHES
The other databases were searched using the following specific terms as text words combined by the Boolean operator “OR”:
thymus therapy; thymic peptide; thymic hormone;Thymustherapie; thymosin; thymosin fraction5: thymosin fractionV; thymulin; thy-
musfactor; thymopentin; thymostimulin; thymic extracts; Ney-Tumorin; Neythymun; Solcothymosin; Thymex; Thymowied; Thym-
Uvocal; Thymoject; thymophysin; Zellmedin-Thymus; THX; TF5; TP-1;THF;TFX;TP5.
These following terms were used to identify the study design:
“therapy”; “treatment”; clinical trial; randomised clinical trial as MeSH terms.
These following terms were used to identify cancer patients:
“cancer”; “tumours”; “neoplasms” as MeSH terms.
Date of last search 10.3.2010
All databases were searched from their inception until March 2010
Appendix 3. Kirkwood formulae
Survival Time (t)=S(t)=exp(-Êt). This transforms for the median survival time to Tmed = - ln (0.5) / Ê. The number ECG of events
in the control group given NCG patients in the control group at median survival time of the intervention group Tmed (MIG) can now
be calculated via ECG = NCG * (1-EXP(-Tmed (MIG)*ln(2)/ Tmed (MCG)). Obviously, the number of events in the intervention group
is EIG= 0.5*NIG. Of note, these calculations assume no censoring of patients up to median follow-up time. With these numbers a
relative risk with an approximate 95% CI can be calculated as implemented in standard meta-analysis software.
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 2, 2011
Date Event Description
1 October 2008 New citation required and major changes Authors: Reviewer team has changed
Objectives: Text was rephrased and the population under study was
restricted to cancer patients with thymus extracts during chemo- or
radiotherapy
Types of interventions: Interventional treatment under study was re-
stricted to thymus extracts given during chemo- or radiotherapy and
interventions in the control group were restricted to no treatment, or
placebo treatment.
Types of outcome measures: Text was rephrased
Acknowledgments/Contributions of authors: the review team has
changed and the text were rephrased/amended accordingly
16 June 2008 Amended Converted to new review format.
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